Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12657923,peak plasma concentrations,"The peak plasma concentrations were 2290 microg/L and 2900 microg/L, respectively.",Toxicokinetics of nortriptyline and amitriptyline: two case reports. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657923/),[μg] / [l],2290,154,DB00321,Amitriptyline
,12657923,peak plasma concentrations,"The peak plasma concentrations were 2290 microg/L and 2900 microg/L, respectively.",Toxicokinetics of nortriptyline and amitriptyline: two case reports. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657923/),[μg] / [l],2900,155,DB00321,Amitriptyline
less,1815435,clearance,Two slow metabolizers were identified (clearance less than 0.10 L/kg/h).,Early individualization of tricyclic antidepressant dosing using a Bayesian pharmacokinetic model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815435/),[l] / [h·kg],0.10,8081,DB00321,Amitriptyline
,1494978,F,"The estimated F value, a fraction of dose reached at systemic circulation, and the MD value, a fraction metabolized to NRT, were 0.044 and 0.020, respectively, after acute administration, indicating first-pass metabolism of AMT.",Pharmacokinetic analysis of amitriptyline and its demethylated metabolite in serum and brain of rats after acute and chronic oral administration of amitriptyline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1494978/),,0.044,8161,DB00321,Amitriptyline
,1494978,MD,"The estimated F value, a fraction of dose reached at systemic circulation, and the MD value, a fraction metabolized to NRT, were 0.044 and 0.020, respectively, after acute administration, indicating first-pass metabolism of AMT.",Pharmacokinetic analysis of amitriptyline and its demethylated metabolite in serum and brain of rats after acute and chronic oral administration of amitriptyline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1494978/),,0.044,8162,DB00321,Amitriptyline
,1494978,MD,"The estimated F value, a fraction of dose reached at systemic circulation, and the MD value, a fraction metabolized to NRT, were 0.044 and 0.020, respectively, after acute administration, indicating first-pass metabolism of AMT.",Pharmacokinetic analysis of amitriptyline and its demethylated metabolite in serum and brain of rats after acute and chronic oral administration of amitriptyline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1494978/),,0.020,8163,DB00321,Amitriptyline
,2791284,minimum concentration,"This procedure for measuring desipramine and its 2-hydroxy metabolite in serum at a minimum concentration of 1 micrograms/L involves high-performance liquid chromatography (HPLC), with ultraviolet detection at 214 nm.",Determination of serum desipramine and 2-hydroxydesipramine for pharmacokinetic applications by HPLC with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791284/),[μg] / [l],1,9110,DB00321,Amitriptyline
,29092731,t<sub>lag</sub>,"Median t<sub>max</sub> was not significantly different (p > 0.05), and median t<sub>lag</sub> was the same (1 hour).",Bioequivalence of cyclobenzaprine hydrochloride extended-release capsule taken intact or sprinkled over applesauce . ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29092731/),h,1,13402,DB00321,Amitriptyline
,19589735,quantification limit,The quantification limit was 0.2 ng/mL within a linear range of 0.2-1000 ng/mL.,Determination of mitragynine in rat plasma by LC-MS/MS: application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19589735/),[ng] / [ml],0.2,19041,DB00321,Amitriptyline
,19589735,maximum plasma concentration,"The following pharmacokinetic parameters were obtained (mean): maximum plasma concentration: 424 ng/mL; time to reach maximum plasma concentration: 1.26 h; elimination half-life: 3.85 h, apparent total clearance: 6.35 L/h/kg, and apparent volume of distribution: 37.90 L/kg.",Determination of mitragynine in rat plasma by LC-MS/MS: application to pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19589735/),[ng] / [ml],424,19042,DB00321,Amitriptyline
,19589735,time to reach maximum plasma concentration,"The following pharmacokinetic parameters were obtained (mean): maximum plasma concentration: 424 ng/mL; time to reach maximum plasma concentration: 1.26 h; elimination half-life: 3.85 h, apparent total clearance: 6.35 L/h/kg, and apparent volume of distribution: 37.90 L/kg.",Determination of mitragynine in rat plasma by LC-MS/MS: application to pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19589735/),h,1.26,19043,DB00321,Amitriptyline
,19589735,elimination half-life,"The following pharmacokinetic parameters were obtained (mean): maximum plasma concentration: 424 ng/mL; time to reach maximum plasma concentration: 1.26 h; elimination half-life: 3.85 h, apparent total clearance: 6.35 L/h/kg, and apparent volume of distribution: 37.90 L/kg.",Determination of mitragynine in rat plasma by LC-MS/MS: application to pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19589735/),h,3.85,19044,DB00321,Amitriptyline
,19589735,apparent total clearance,"The following pharmacokinetic parameters were obtained (mean): maximum plasma concentration: 424 ng/mL; time to reach maximum plasma concentration: 1.26 h; elimination half-life: 3.85 h, apparent total clearance: 6.35 L/h/kg, and apparent volume of distribution: 37.90 L/kg.",Determination of mitragynine in rat plasma by LC-MS/MS: application to pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19589735/),[l] / [h·kg],6.35,19045,DB00321,Amitriptyline
,19589735,apparent volume of distribution,"The following pharmacokinetic parameters were obtained (mean): maximum plasma concentration: 424 ng/mL; time to reach maximum plasma concentration: 1.26 h; elimination half-life: 3.85 h, apparent total clearance: 6.35 L/h/kg, and apparent volume of distribution: 37.90 L/kg.",Determination of mitragynine in rat plasma by LC-MS/MS: application to pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19589735/),[l] / [kg],37.90,19046,DB00321,Amitriptyline
,1771652,Plasma concentrations,Plasma concentrations of AMI (510 ng/ml) and nortriptyline (NOR; 320 ng/ml) were very high and the half-life of AMI was about 120 h.,Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),[ng] / [ml],510,21188,DB00321,Amitriptyline
,1771652,Plasma concentrations,Plasma concentrations of AMI (510 ng/ml) and nortriptyline (NOR; 320 ng/ml) were very high and the half-life of AMI was about 120 h.,Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),[ng] / [ml],320,21189,DB00321,Amitriptyline
,1771652,half-life,Plasma concentrations of AMI (510 ng/ml) and nortriptyline (NOR; 320 ng/ml) were very high and the half-life of AMI was about 120 h.,Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),h,120,21190,DB00321,Amitriptyline
,1771652,metabolic ratio,"The debrisoquine metabolic ratio was 0.55 and 0.79 on two occasions, which shows that she had no deficiency of cytochrome P450IID6.",Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),,0.55,21191,DB00321,Amitriptyline
,1771652,metabolic ratio,"The debrisoquine metabolic ratio was 0.55 and 0.79 on two occasions, which shows that she had no deficiency of cytochrome P450IID6.",Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),,0.79,21192,DB00321,Amitriptyline
,21396231,total chromatographic run time,The method had a total chromatographic run time of 3.5 min and linear calibration curves over the concentration range of 0.2-100 ng/mL.,A rapid and sensitive liquid chromatography-tandem mass spectrometry method for determination of olopatadine concentration in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21396231/),min,3.5,21801,DB00321,Amitriptyline
,19682959,flow rate,"A mobile phase containing 10mM ammonium acetate (pH 3.6)-methanol-acetonitrile (27:68:5, v/v/v) was used isocratically eluting at a flow rate of 0.22ml/min.",Quantification of prochlorperazine maleate in human plasma by liquid chromatography-mass spectrometry: Application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19682959/),[ml] / [min],0.22,26009,DB00321,Amitriptyline
,19682959,extraction recovery,"The average extraction recovery of prochlorperazine and internal standard were 81.8+/-2.2% and 79.5+/-3.7%, respectively.",Quantification of prochlorperazine maleate in human plasma by liquid chromatography-mass spectrometry: Application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19682959/),%,81.8,26010,DB00321,Amitriptyline
,19682959,extraction recovery,"The average extraction recovery of prochlorperazine and internal standard were 81.8+/-2.2% and 79.5+/-3.7%, respectively.",Quantification of prochlorperazine maleate in human plasma by liquid chromatography-mass spectrometry: Application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19682959/),%,79.5,26011,DB00321,Amitriptyline
,7361577,biological half-life,The biological half-life of amitriptyline in the myocardium was about 37.7 min.,"Myocardial pharmacokinetics of amitriptyline and clomipramine in the isolated, perfused rabbit heart. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7361577/),min,37.7,27473,DB00321,Amitriptyline
,7361577,accumulated amount at steady state,and the accumulated amount at steady state was calculated to be 1055 micrograms.,"Myocardial pharmacokinetics of amitriptyline and clomipramine in the isolated, perfused rabbit heart. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7361577/),μg,1055,27474,DB00321,Amitriptyline
,9597561,area under the concentration--time curve (AUC0-24),"Mean values for area under the concentration--time curve (AUC0-24) for the OROS and IR formulations were 1,265 and 1,393 ng.",Multiple-dose pharmacokinetics and pharmacodynamics of OROS and immediate-release amitriptyline hydrochloride formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9597561/),ng,"1,265",29397,DB00321,Amitriptyline
,9597561,area under the concentration--time curve (AUC0-24),"Mean values for area under the concentration--time curve (AUC0-24) for the OROS and IR formulations were 1,265 and 1,393 ng.",Multiple-dose pharmacokinetics and pharmacodynamics of OROS and immediate-release amitriptyline hydrochloride formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9597561/),ng,"1,393",29398,DB00321,Amitriptyline
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,7.8,30263,DB00321,Amitriptyline
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,11.6,30264,DB00321,Amitriptyline
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,16,30265,DB00321,Amitriptyline
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,17.8,30266,DB00321,Amitriptyline
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,20.9,30267,DB00321,Amitriptyline
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,31,30268,DB00321,Amitriptyline
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,35,30269,DB00321,Amitriptyline
,11197075,Ki (inhibition constant),"Studies with control liver microsomes showed that amitriptyline and imipramine added to the incubation mixture in-vitro, competitively inhibited N-demethylation (Ki (inhibition constant) = 16 microM and 164 microM, respectively) and 5-sulphoxidation (Ki = 57 microM and 86 microM, respectively) of perazine, amitriptyline being a more potent inhibitor of perazine metabolism, especially with respect to N-demethylation.",Different effects of amitriptyline and imipramine on the pharmacokinetics and metabolism of perazine in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11197075/),μM,16,34677,DB00321,Amitriptyline
,11197075,Ki (inhibition constant),"Studies with control liver microsomes showed that amitriptyline and imipramine added to the incubation mixture in-vitro, competitively inhibited N-demethylation (Ki (inhibition constant) = 16 microM and 164 microM, respectively) and 5-sulphoxidation (Ki = 57 microM and 86 microM, respectively) of perazine, amitriptyline being a more potent inhibitor of perazine metabolism, especially with respect to N-demethylation.",Different effects of amitriptyline and imipramine on the pharmacokinetics and metabolism of perazine in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11197075/),μM,164,34678,DB00321,Amitriptyline
,11197075,Ki,"Studies with control liver microsomes showed that amitriptyline and imipramine added to the incubation mixture in-vitro, competitively inhibited N-demethylation (Ki (inhibition constant) = 16 microM and 164 microM, respectively) and 5-sulphoxidation (Ki = 57 microM and 86 microM, respectively) of perazine, amitriptyline being a more potent inhibitor of perazine metabolism, especially with respect to N-demethylation.",Different effects of amitriptyline and imipramine on the pharmacokinetics and metabolism of perazine in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11197075/),μM,57,34679,DB00321,Amitriptyline
,11197075,Ki,"Studies with control liver microsomes showed that amitriptyline and imipramine added to the incubation mixture in-vitro, competitively inhibited N-demethylation (Ki (inhibition constant) = 16 microM and 164 microM, respectively) and 5-sulphoxidation (Ki = 57 microM and 86 microM, respectively) of perazine, amitriptyline being a more potent inhibitor of perazine metabolism, especially with respect to N-demethylation.",Different effects of amitriptyline and imipramine on the pharmacokinetics and metabolism of perazine in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11197075/),μM,86,34680,DB00321,Amitriptyline
,19243711,AUC(0-168),"Mean observed values for dose-dependent pharmacokinetic parameters of CER 15 and 30 mg were as follows: AUC(0-168), 318.3 and 736.6 ng . h/mL, respectively; AUC(0-infinity)), 354.1 and 779.9 ng . h/mL; and C(max), 8.3 and 19.9 ng/mL.","A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19243711/),[h·ng] / [ml],318.3,37636,DB00321,Amitriptyline
,19243711,AUC(0-168),"Mean observed values for dose-dependent pharmacokinetic parameters of CER 15 and 30 mg were as follows: AUC(0-168), 318.3 and 736.6 ng . h/mL, respectively; AUC(0-infinity)), 354.1 and 779.9 ng . h/mL; and C(max), 8.3 and 19.9 ng/mL.","A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19243711/),[h·ng] / [ml],736.6,37637,DB00321,Amitriptyline
,19243711,AUC(0-infinity)),"Mean observed values for dose-dependent pharmacokinetic parameters of CER 15 and 30 mg were as follows: AUC(0-168), 318.3 and 736.6 ng . h/mL, respectively; AUC(0-infinity)), 354.1 and 779.9 ng . h/mL; and C(max), 8.3 and 19.9 ng/mL.","A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19243711/),[h·ng] / [ml],354.1,37638,DB00321,Amitriptyline
,19243711,AUC(0-infinity)),"Mean observed values for dose-dependent pharmacokinetic parameters of CER 15 and 30 mg were as follows: AUC(0-168), 318.3 and 736.6 ng . h/mL, respectively; AUC(0-infinity)), 354.1 and 779.9 ng . h/mL; and C(max), 8.3 and 19.9 ng/mL.","A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19243711/),[h·ng] / [ml],779.9,37639,DB00321,Amitriptyline
,19243711,C(max),"Mean observed values for dose-dependent pharmacokinetic parameters of CER 15 and 30 mg were as follows: AUC(0-168), 318.3 and 736.6 ng . h/mL, respectively; AUC(0-infinity)), 354.1 and 779.9 ng . h/mL; and C(max), 8.3 and 19.9 ng/mL.","A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19243711/),[ng] / [ml],8.3,37640,DB00321,Amitriptyline
,19243711,C(max),"Mean observed values for dose-dependent pharmacokinetic parameters of CER 15 and 30 mg were as follows: AUC(0-168), 318.3 and 736.6 ng . h/mL, respectively; AUC(0-infinity)), 354.1 and 779.9 ng . h/mL; and C(max), 8.3 and 19.9 ng/mL.","A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19243711/),[ng] / [ml],19.9,37641,DB00321,Amitriptyline
,19243711,Tmax,Median observed Tmax was 6.0 hours for both CER doses; mean t(1/2) was 33.4 hours for CER 15 mg and 32.0 hours for CER 30 mg.,"A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19243711/),h,6.0,37642,DB00321,Amitriptyline
,19243711,t(1/2),Median observed Tmax was 6.0 hours for both CER doses; mean t(1/2) was 33.4 hours for CER 15 mg and 32.0 hours for CER 30 mg.,"A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19243711/),h,33.4,37643,DB00321,Amitriptyline
,19243711,t(1/2),Median observed Tmax was 6.0 hours for both CER doses; mean t(1/2) was 33.4 hours for CER 15 mg and 32.0 hours for CER 30 mg.,"A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19243711/),h,32.0,37644,DB00321,Amitriptyline
,19243711,bioavailability,"The bioavailability of the 2 doses, as indicated by the least squares mean AUC(0-infinity), was 330.3 ng .","A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19243711/),ng,330.3,37645,DB00321,Amitriptyline
,1389934,Cmax,"3. No differences were found between treatments in mean Cmax and AUC values of oxycodone which varied from 34 to 38 ng ml-1 and from 208 to 245 ng ml-1 h, respectively.",The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389934/),[ng] / [ml],34 to 38,38910,DB00321,Amitriptyline
,1389934,AUC,"3. No differences were found between treatments in mean Cmax and AUC values of oxycodone which varied from 34 to 38 ng ml-1 and from 208 to 245 ng ml-1 h, respectively.",The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389934/),[h·ng] / [ml],208 to 245,38911,DB00321,Amitriptyline
,1389934,tmax,The median tmax of oxycodone was 1 h in all groups.,The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389934/),h,1,38912,DB00321,Amitriptyline
,1389934,bioavailability,The bioavailability of oral relative to i.m. oxycodone was 60%.,The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389934/),%,60,38913,DB00321,Amitriptyline
,1389934,renal clearance,The mean renal clearance of oxycodone was 0.07-0.08 l min-1.,The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389934/),[l] / [min],0.07-0.08,38914,DB00321,Amitriptyline
,7721229,elimination half-life time (t1/2,"Kinetics of amitriptyline (AMI), its demethylated metabolites nortriptyline (NOR) and demethylnortriptyline (DM-NOR), and its hydroxylated metabolites, the E and Z isomers or 10-hydroxy-amitriptyline (E- and Z-10-OH-AMI) and of 10-hydroxynortriptyline (E- and Z-10-OH-NOR) were studied in plasma and brain from Swiss CD1 mice after six successive intraperitoneal injections of amitriptyline (10 mg/kg) administered every elimination half-life time (t1/2 = 3.1 h) to obtain the steady state.",Mice plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after half-life repeated administration. Comparison with acute administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7721229/),h,3.1,50913,DB00321,Amitriptyline
,34093211,IC50,Amitriptyline and nortriptyline were found to inhibit OCT1 in recombinant cells with IC50 values of 28.6 and 40.4 µM.,"Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34093211/),μM,28.6,51397,DB00321,Amitriptyline
,34093211,IC50,Amitriptyline and nortriptyline were found to inhibit OCT1 in recombinant cells with IC50 values of 28.6 and 40.4 µM.,"Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34093211/),μM,40.4,51398,DB00321,Amitriptyline
,15355124,oral clearance,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),[ml] / [min],22-36,55128,DB00321,Amitriptyline
,15355124,renal clearance,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),[ml] / [min],10-20,55129,DB00321,Amitriptyline
,15355124,half-life,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),h,19-25,55130,DB00321,Amitriptyline
,15355124,absolute bioavailability,"The absolute bioavailability, or oral availability, of topiramate is 81-95% and is not affected by food.",Pharmacokinetic interactions of topiramate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),%,81-95,55131,DB00321,Amitriptyline
,15355124,oral availability,"The absolute bioavailability, or oral availability, of topiramate is 81-95% and is not affected by food.",Pharmacokinetic interactions of topiramate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),%,81-95,55132,DB00321,Amitriptyline
,18806030,Peak Paco2,"Peak Paco2 was significantly higher in the amitriptyline group (58.4+/-1.6 mm Hg; mean SD, P<0.005) and in the combination group (57.4+/-1.0 mm Hg, P<0.02) than in the control group (50.2+/-5.2 mm Hg).","The effect of amitriptyline, gabapentin, and carbamazepine on morphine-induced hypercarbia in rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806030/),hg·mm,58.4,55481,DB00321,Amitriptyline
,18806030,Peak Paco2,"Peak Paco2 was significantly higher in the amitriptyline group (58.4+/-1.6 mm Hg; mean SD, P<0.005) and in the combination group (57.4+/-1.0 mm Hg, P<0.02) than in the control group (50.2+/-5.2 mm Hg).","The effect of amitriptyline, gabapentin, and carbamazepine on morphine-induced hypercarbia in rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806030/),hg·mm,57.4,55482,DB00321,Amitriptyline
,18806030,Peak Paco2,"Peak Paco2 was significantly higher in the amitriptyline group (58.4+/-1.6 mm Hg; mean SD, P<0.005) and in the combination group (57.4+/-1.0 mm Hg, P<0.02) than in the control group (50.2+/-5.2 mm Hg).","The effect of amitriptyline, gabapentin, and carbamazepine on morphine-induced hypercarbia in rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806030/),hg·mm,50.2,55483,DB00321,Amitriptyline
,1305963,acrophases,The fastest elimination of amitriptyline was observed in the dark phase (the acrophases for clearance were ca. 11 p.m. for iv administration and ca. 10 p.m. for po administration).,Circadian changes in the elimination of amitriptyline in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1305963/),m·p,11,55749,DB00321,Amitriptyline
,1305963,acrophases,The fastest elimination of amitriptyline was observed in the dark phase (the acrophases for clearance were ca. 11 p.m. for iv administration and ca. 10 p.m. for po administration).,Circadian changes in the elimination of amitriptyline in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1305963/),p,10,55750,DB00321,Amitriptyline
,7389249,unbound fraction,"The mean unbound fraction of AT and NT in plasma was 5.4% and 8.3%, respectively.",Interindividual differences in amitriptyline demethylation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389249/),%,5.4,56807,DB00321,Amitriptyline
,7389249,unbound fraction,"The mean unbound fraction of AT and NT in plasma was 5.4% and 8.3%, respectively.",Interindividual differences in amitriptyline demethylation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389249/),%,8.3,56808,DB00321,Amitriptyline
,7389249,systemic availability,The mean systemic availability of oral relative to intramuscular AT and NT was 43% and 61%.,Interindividual differences in amitriptyline demethylation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389249/),%,43,56809,DB00321,Amitriptyline
,7389249,systemic availability,The mean systemic availability of oral relative to intramuscular AT and NT was 43% and 61%.,Interindividual differences in amitriptyline demethylation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389249/),%,61,56810,DB00321,Amitriptyline
,7389249,oral blood clearance,The calculated mean oral blood clearance of AT as measured by dose (oral)/AUC was 1.6 1/min.,Interindividual differences in amitriptyline demethylation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389249/),[1] / [min],1.6,56811,DB00321,Amitriptyline
,7389249,oral clearance,The estimated oral clearance of AT from demethylation ranged from 0.21 to 1.80 1/min.,Interindividual differences in amitriptyline demethylation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389249/),[1] / [min],0.21 to 1.80,56812,DB00321,Amitriptyline
,25989225,CMAX,The range of amitriptyline CMAX for the remaining fasted dogs (n = 3) was 22.8-64.5 ng/mL compared to 30.6-127 ng/mL for the fed dogs (n = 5).,Evaluation of the pharmacokinetics of oral amitriptyline and its active metabolite nortriptyline in fed and fasted Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25989225/),[ng] / [ml],22.8-64.5,58327,DB00321,Amitriptyline
,25989225,CMAX,The range of amitriptyline CMAX for the remaining fasted dogs (n = 3) was 22.8-64.5 ng/mL compared to 30.6-127 ng/mL for the fed dogs (n = 5).,Evaluation of the pharmacokinetics of oral amitriptyline and its active metabolite nortriptyline in fed and fasted Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25989225/),[ng] / [ml],30.6-127,58328,DB00321,Amitriptyline
,25989225,AUCINF,The range of the amitriptyline AUCINF for the three fasted dogs was 167-720 h·ng/mL compared to 287-1146 h·ng/mL for fed dogs.,Evaluation of the pharmacokinetics of oral amitriptyline and its active metabolite nortriptyline in fed and fasted Greyhound dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25989225/),[h·ng] / [ml],167-720,58329,DB00321,Amitriptyline
,25989225,AUCINF,The range of the amitriptyline AUCINF for the three fasted dogs was 167-720 h·ng/mL compared to 287-1146 h·ng/mL for fed dogs.,Evaluation of the pharmacokinetics of oral amitriptyline and its active metabolite nortriptyline in fed and fasted Greyhound dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25989225/),[h·ng] / [ml],287-1146,58330,DB00321,Amitriptyline
,25989225,relative bioavailability,The relative bioavailability of amitriptyline in fasted dogs compared to fed dogs was 69-91% (n = 3).,Evaluation of the pharmacokinetics of oral amitriptyline and its active metabolite nortriptyline in fed and fasted Greyhound dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25989225/),%,69-91,58331,DB00321,Amitriptyline
,26771316,Elimination half-life,Elimination half-life varied from 1.6 to 91.2 hours.,Pharmacokinetics of Amitriptyline HCl and Its Metabolites in Healthy African Grey Parrots ( Psittacus erithacus ) and Cockatoos (Cacatua Species). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26771316/),h,1.6 to 91.2,69255,DB00321,Amitriptyline
,18991473,t(max),"The pharmacokinetic profile of CER 30 mg was characterized by an absorption phase with a median t(max) of approximately 6 hours, compared with the initial peak of CIR (following the first dose) of about 4 hours.","Single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults : a randomized, open-label, two-period crossover, single-centre study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18991473/),h,6,74190,DB00321,Amitriptyline
,18991473,initial peak,"The pharmacokinetic profile of CER 30 mg was characterized by an absorption phase with a median t(max) of approximately 6 hours, compared with the initial peak of CIR (following the first dose) of about 4 hours.","Single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults : a randomized, open-label, two-period crossover, single-centre study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18991473/),,4,74191,DB00321,Amitriptyline
,18991473,plasma concentrations,Mean plasma concentrations at 4 hours were comparable (12.1 ng/mL for CER; 12.4 ng/mL for CIR).,"Single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults : a randomized, open-label, two-period crossover, single-centre study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18991473/),[ng] / [ml],12.1,74192,DB00321,Amitriptyline
,18991473,plasma concentrations,Mean plasma concentrations at 4 hours were comparable (12.1 ng/mL for CER; 12.4 ng/mL for CIR).,"Single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults : a randomized, open-label, two-period crossover, single-centre study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18991473/),[ng] / [ml],12.4,74193,DB00321,Amitriptyline
,18991473,C(max),The C(max) for CER 30 mg was 19.2 ng/mL (median t(max) = 6 hours) and for CIR (following the third dose) was 18.1 ng/mL (median t(max) = 12 hours).,"Single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults : a randomized, open-label, two-period crossover, single-centre study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18991473/),[ng] / [ml],19.2,74194,DB00321,Amitriptyline
,18991473,C(max),The C(max) for CER 30 mg was 19.2 ng/mL (median t(max) = 6 hours) and for CIR (following the third dose) was 18.1 ng/mL (median t(max) = 12 hours).,"Single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults : a randomized, open-label, two-period crossover, single-centre study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18991473/),[ng] / [ml],18.1,74195,DB00321,Amitriptyline
,18991473,t(max),The C(max) for CER 30 mg was 19.2 ng/mL (median t(max) = 6 hours) and for CIR (following the third dose) was 18.1 ng/mL (median t(max) = 12 hours).,"Single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults : a randomized, open-label, two-period crossover, single-centre study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18991473/),h,6,74196,DB00321,Amitriptyline
,18991473,t(max),The C(max) for CER 30 mg was 19.2 ng/mL (median t(max) = 6 hours) and for CIR (following the third dose) was 18.1 ng/mL (median t(max) = 12 hours).,"Single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults : a randomized, open-label, two-period crossover, single-centre study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18991473/),[ng] / [ml],18.1,74197,DB00321,Amitriptyline
,18991473,t(max),The C(max) for CER 30 mg was 19.2 ng/mL (median t(max) = 6 hours) and for CIR (following the third dose) was 18.1 ng/mL (median t(max) = 12 hours).,"Single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults : a randomized, open-label, two-period crossover, single-centre study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18991473/),h,12,74198,DB00321,Amitriptyline
,4023050,half-life,The results indicate that amitriptylinoxide is more rapidly absorbed than amitriptyline and eliminated with a mean half-life of 1.5 hours.,Single oral dose pharmacokinetics of amitriptylinoxide and amitriptyline in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4023050/),h,1.5,77762,DB00321,Amitriptyline
,8748391,t1/2,"In addition, the t1/2 of the active moiety was prolonged (19 h in young subjects versus about 25 h in elderly and renal disease patients).","Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8748391/),h,19,81649,DB00321,Amitriptyline
,8748391,t1/2,"In addition, the t1/2 of the active moiety was prolonged (19 h in young subjects versus about 25 h in elderly and renal disease patients).","Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8748391/),h,25,81650,DB00321,Amitriptyline
,12934651,maximum concentrations (Cmax),"After the oral administration of both products at the dose of 50 mg, the mean maximum concentrations (Cmax) were 36.4 and 29.7 ng/mL, and the mean areas under the concentration-time curve (AUC(0-96)) were 1180.2 and 1010.7 ng.h/mL for ATP and Saroten retard, respectively.",A new formulation of controlled release amitriptyline pellets and its in vivo/in vitro assessments. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12934651/),[ng] / [ml],36.4,83202,DB00321,Amitriptyline
,12934651,maximum concentrations (Cmax),"After the oral administration of both products at the dose of 50 mg, the mean maximum concentrations (Cmax) were 36.4 and 29.7 ng/mL, and the mean areas under the concentration-time curve (AUC(0-96)) were 1180.2 and 1010.7 ng.h/mL for ATP and Saroten retard, respectively.",A new formulation of controlled release amitriptyline pellets and its in vivo/in vitro assessments. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12934651/),[ng] / [ml],29.7,83203,DB00321,Amitriptyline
,12934651,areas under the concentration-time curve (AUC(0-96)),"After the oral administration of both products at the dose of 50 mg, the mean maximum concentrations (Cmax) were 36.4 and 29.7 ng/mL, and the mean areas under the concentration-time curve (AUC(0-96)) were 1180.2 and 1010.7 ng.h/mL for ATP and Saroten retard, respectively.",A new formulation of controlled release amitriptyline pellets and its in vivo/in vitro assessments. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12934651/),[h·ng] / [ml],1180.2,83204,DB00321,Amitriptyline
,12934651,areas under the concentration-time curve (AUC(0-96)),"After the oral administration of both products at the dose of 50 mg, the mean maximum concentrations (Cmax) were 36.4 and 29.7 ng/mL, and the mean areas under the concentration-time curve (AUC(0-96)) were 1180.2 and 1010.7 ng.h/mL for ATP and Saroten retard, respectively.",A new formulation of controlled release amitriptyline pellets and its in vivo/in vitro assessments. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12934651/),[h·ng] / [ml],1010.7,83205,DB00321,Amitriptyline
,12934651,time to reach the maximum concentrations (Tmax),The time to reach the maximum concentrations (Tmax) was 6 h for both formulations.,A new formulation of controlled release amitriptyline pellets and its in vivo/in vitro assessments. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12934651/),h,6,83206,DB00321,Amitriptyline
,11808825,plasma clearance,"Cyclobenzaprine plasma clearance was 689 ml/min, and the bioavailability of a 5 mg oral dose was 0.55.","Cyclobenzaprine pharmacokinetics, including the effects of age, gender, and hepatic insufficiency. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808825/),[ml] / [min],689,85789,DB00321,Amitriptyline
,11808825,bioavailability,"Cyclobenzaprine plasma clearance was 689 ml/min, and the bioavailability of a 5 mg oral dose was 0.55.","Cyclobenzaprine pharmacokinetics, including the effects of age, gender, and hepatic insufficiency. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808825/),,0.55,85790,DB00321,Amitriptyline
,11808825,effective,"There was about a fourfold accumulation of the drug in plasma on multiple dosing, corresponding to an effective half-life of 18 hours.","Cyclobenzaprine pharmacokinetics, including the effects of age, gender, and hepatic insufficiency. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808825/),h,18,85791,DB00321,Amitriptyline
,11808825,half-life,"There was about a fourfold accumulation of the drug in plasma on multiple dosing, corresponding to an effective half-life of 18 hours.","Cyclobenzaprine pharmacokinetics, including the effects of age, gender, and hepatic insufficiency. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808825/),h,18,85792,DB00321,Amitriptyline
,7957453,tmax,"Absorption and elimination of AMI were rapid (tmax = 0.37 h and 0.42 h, and t1/2 = 3.2 h and 3.6 h in plasma and brain, respectively).",Plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after acute intraperitoneal injection in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957453/),h,0.37,85886,DB00321,Amitriptyline
,7957453,tmax,"Absorption and elimination of AMI were rapid (tmax = 0.37 h and 0.42 h, and t1/2 = 3.2 h and 3.6 h in plasma and brain, respectively).",Plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after acute intraperitoneal injection in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957453/),h,0.42,85887,DB00321,Amitriptyline
,7957453,t1/2,"Absorption and elimination of AMI were rapid (tmax = 0.37 h and 0.42 h, and t1/2 = 3.2 h and 3.6 h in plasma and brain, respectively).",Plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after acute intraperitoneal injection in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957453/),h,3.2,85888,DB00321,Amitriptyline
,7957453,t1/2,"Absorption and elimination of AMI were rapid (tmax = 0.37 h and 0.42 h, and t1/2 = 3.2 h and 3.6 h in plasma and brain, respectively).",Plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after acute intraperitoneal injection in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957453/),h,3.6,85889,DB00321,Amitriptyline
,4049459,t 1/2,"However, the variation in t 1/2 was extremely large in both the CAPD and normal renal function groups (range 15-34 h and 24-70 h, respectively).",Evaluation of amitriptyline pharmacokinetics during peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4049459/),h,15-34,87717,DB00321,Amitriptyline
,4049459,t 1/2,"However, the variation in t 1/2 was extremely large in both the CAPD and normal renal function groups (range 15-34 h and 24-70 h, respectively).",Evaluation of amitriptyline pharmacokinetics during peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4049459/),h,24-70,87718,DB00321,Amitriptyline
,19220066,t(max),The pharmacokinetics of CER 30 mg were characterized by an absorption phase with a median t(max) of 8 hours compared with an initial peak for CIR (following the first dose) at about 5 hours.,"Comparison of the single-dose pharmacokinetics of once-daily cyclobenzaprine extended-release 30 mg and cyclobenzaprine immediate-release 10 mg three times daily in the elderly: a randomized, open-label, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19220066/),h,8,90040,DB00321,Amitriptyline
,7032872,elimination half-life,Trazodone is excreted primarily as metabolites by the kidneys and possesses a biphasic elimination half-life of 4.4 hours for the first 10 hours and 7.5 hours for the next 24 hours.,"Trazodone (Desyrel, Mead-Johnson Pharmaceutical Division). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7032872/),h,4.4,93210,DB00321,Amitriptyline
,7032872,elimination half-life,Trazodone is excreted primarily as metabolites by the kidneys and possesses a biphasic elimination half-life of 4.4 hours for the first 10 hours and 7.5 hours for the next 24 hours.,"Trazodone (Desyrel, Mead-Johnson Pharmaceutical Division). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7032872/),h,7.5,93211,DB00321,Amitriptyline
,3515929,systemic availability,The mean systemic availability is approximately 4 percent.,Metabolism and disposition of buspirone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515929/),%,4,93421,DB00321,Amitriptyline
,3515929,Half-life,Half-life values observed in healthy volunteers ranged from two to 33 hours.,Metabolism and disposition of buspirone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515929/),h,two to 33,93422,DB00321,Amitriptyline
,3515929,half-life,Mean half-life values observed in healthy volunteers in the 14 studies conducted to date ranged from 2 +/- 1 to 11 +/- 3 hours.,Metabolism and disposition of buspirone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515929/),h,2,93423,DB00321,Amitriptyline
,3515929,half-life,Mean half-life values observed in healthy volunteers in the 14 studies conducted to date ranged from 2 +/- 1 to 11 +/- 3 hours.,Metabolism and disposition of buspirone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515929/),h,11,93424,DB00321,Amitriptyline
,6636256,Absolute recoveries,Absolute recoveries were 87-97%.,Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),%,87-97,96511,DB00321,Amitriptyline
,6636256,Detection limits,"Detection limits under the conditions described were 2 ng/ml for AMI, DOX, and IMI, 4 ng/ml for NORT, DESDOX, and DESIP, and 10 ng/ml for PRO.",Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),[ng] / [ml],2,96512,DB00321,Amitriptyline
,6636256,Detection limits,"Detection limits under the conditions described were 2 ng/ml for AMI, DOX, and IMI, 4 ng/ml for NORT, DESDOX, and DESIP, and 10 ng/ml for PRO.",Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),[ng] / [ml],4,96513,DB00321,Amitriptyline
,6636256,Detection limits,"Detection limits under the conditions described were 2 ng/ml for AMI, DOX, and IMI, 4 ng/ml for NORT, DESDOX, and DESIP, and 10 ng/ml for PRO.",Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),[ng] / [ml],10,96514,DB00321,Amitriptyline
less,6636256,total assay time,The total assay time was less than 10 min for DESIP and 12 min for PRO.,Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),min,10,96515,DB00321,Amitriptyline
,6636256,total assay time,The total assay time was less than 10 min for DESIP and 12 min for PRO.,Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),min,12,96516,DB00321,Amitriptyline
,12012142,area under the plasma concentration-time curve (AUC(AT)),"The mean area under the plasma concentration-time curve (AUC(AT)) of CYP2C19 poor metabolizers (PMs, n=6) was significantly higher than that of CYP2C19 extensive metabolizers (EMs, n=6) (2207+/-501 ng/ml x h(-1) vs 1596+/-406 ng/ml x h(-1), P<0.05).",The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012142/),[ml·ng] / [h],2207,96953,DB00321,Amitriptyline
,12012142,area under the plasma concentration-time curve (AUC(AT)),"The mean area under the plasma concentration-time curve (AUC(AT)) of CYP2C19 poor metabolizers (PMs, n=6) was significantly higher than that of CYP2C19 extensive metabolizers (EMs, n=6) (2207+/-501 ng/ml x h(-1) vs 1596+/-406 ng/ml x h(-1), P<0.05).",The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012142/),[ml·ng] / [h],1596,96954,DB00321,Amitriptyline
,12012142,AUC(NT(0-)(infinity)()),"In contrast, the mean AUC(NT(0-)(infinity)()) of PMs was significantly lower than that of EMs (294+/-70 ng/ml x h(-1) vs 684+/-130 ng/ml x h(-1), P<0.0001).",The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012142/),[ml·ng] / [h],294,96955,DB00321,Amitriptyline
,12012142,AUC(NT(0-)(infinity)()),"In contrast, the mean AUC(NT(0-)(infinity)()) of PMs was significantly lower than that of EMs (294+/-70 ng/ml x h(-1) vs 684+/-130 ng/ml x h(-1), P<0.0001).",The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012142/),[ml·ng] / [h],684,96956,DB00321,Amitriptyline
,12012142,clearance,"Other pharmacokinetic parameters such as clearance, half-life, maximum plasma concentration, and time to peak plasma concentration showed no significant difference between PMs and EMs (0.41+/-0.12 l /h x kg(-1) vs 0.50+/-0.15 l /h x kg(-1), 25.0+/-6.2 h vs 24.1+/-4.4 h, 96+/-25 ng/ml vs 75+/-27 ng/ml, 4.0+/-1.4 h vs 3.7+/-1.5 h, respectively).",The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012142/),[h·l] / [kg],0.41,96957,DB00321,Amitriptyline
,12012142,time to peak plasma concentration,"Other pharmacokinetic parameters such as clearance, half-life, maximum plasma concentration, and time to peak plasma concentration showed no significant difference between PMs and EMs (0.41+/-0.12 l /h x kg(-1) vs 0.50+/-0.15 l /h x kg(-1), 25.0+/-6.2 h vs 24.1+/-4.4 h, 96+/-25 ng/ml vs 75+/-27 ng/ml, 4.0+/-1.4 h vs 3.7+/-1.5 h, respectively).",The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012142/),h,4.0,96958,DB00321,Amitriptyline
,12012142,time to peak plasma concentration,"Other pharmacokinetic parameters such as clearance, half-life, maximum plasma concentration, and time to peak plasma concentration showed no significant difference between PMs and EMs (0.41+/-0.12 l /h x kg(-1) vs 0.50+/-0.15 l /h x kg(-1), 25.0+/-6.2 h vs 24.1+/-4.4 h, 96+/-25 ng/ml vs 75+/-27 ng/ml, 4.0+/-1.4 h vs 3.7+/-1.5 h, respectively).",The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012142/),h,3.7,96959,DB00321,Amitriptyline
,8685072,MR,The mean MR increased from 0.13 to 0.27 (P<0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P<0.05).,"Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.13,105121,DB00321,Amitriptyline
,8685072,MR,The mean MR increased from 0.13 to 0.27 (P<0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P<0.05).,"Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.27,105122,DB00321,Amitriptyline
,8685072,MR,The mean MR increased from 0.13 to 0.27 (P<0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P<0.05).,"Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0,105123,DB00321,Amitriptyline
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.24,105124,DB00321,Amitriptyline
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.34,105125,DB00321,Amitriptyline
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.33,105126,DB00321,Amitriptyline
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.58,105127,DB00321,Amitriptyline
,7428796,Pd1/2,It was possible to detect DTS for 228-300 h after the last oral dose and the mean Pd1/2 of this decline of pharmacodynamic effect was observed to be 135 h.,Decreased tyramine sensitivity after discontinuation of amitriptyline therapy. An index of pharmacodynamic half-life. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7428796/),h,135,106227,DB00321,Amitriptyline
,7428796,elimination plasma half-life (t1/2),"However, no measurable amount of AT or NT was present after 84 h and the mean elimination plasma half-life (t1/2) of AT and NT were 37.7 and 38.9 h, respectively.",Decreased tyramine sensitivity after discontinuation of amitriptyline therapy. An index of pharmacodynamic half-life. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7428796/),h,37.7,106228,DB00321,Amitriptyline
,7428796,elimination plasma half-life (t1/2),"However, no measurable amount of AT or NT was present after 84 h and the mean elimination plasma half-life (t1/2) of AT and NT were 37.7 and 38.9 h, respectively.",Decreased tyramine sensitivity after discontinuation of amitriptyline therapy. An index of pharmacodynamic half-life. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7428796/),h,38.9,106229,DB00321,Amitriptyline
,2677125,Elimination half-life,Elimination half-life of lofepramine was 2.5 h and that of amitriptyline was 31 h.,Pharmacokinetics of lofepramine and amitriptyline in elderly healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2677125/),h,2.5,108167,DB00321,Amitriptyline
,2677125,Elimination half-life,Elimination half-life of lofepramine was 2.5 h and that of amitriptyline was 31 h.,Pharmacokinetics of lofepramine and amitriptyline in elderly healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2677125/),h,31,108168,DB00321,Amitriptyline
,26469370,clearance,"Following intravenous administration, the clearance and central compartment (Vc) in plasma were 1.32 L/min and 147 L, respectively.","Population Pharmacokinetics of Amitriptyline After Intrathecal, Epidural, and Intravenous Administration in Sheep. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26469370/),[l] / [min],1.32,108402,DB00321,Amitriptyline
,26469370,central compartment (Vc),"Following intravenous administration, the clearance and central compartment (Vc) in plasma were 1.32 L/min and 147 L, respectively.","Population Pharmacokinetics of Amitriptyline After Intrathecal, Epidural, and Intravenous Administration in Sheep. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26469370/),l,147,108403,DB00321,Amitriptyline
,26469370,Vc,"The IT Vc after IT administration and the EPI Vc after EPI administration were 2.4 and 48.9 mL, respectively.","Population Pharmacokinetics of Amitriptyline After Intrathecal, Epidural, and Intravenous Administration in Sheep. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26469370/),ml,2.4,108404,DB00321,Amitriptyline
,26469370,Vc,"The IT Vc after IT administration and the EPI Vc after EPI administration were 2.4 and 48.9 mL, respectively.","Population Pharmacokinetics of Amitriptyline After Intrathecal, Epidural, and Intravenous Administration in Sheep. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26469370/),ml,48.9,108405,DB00321,Amitriptyline
,26469370,bioavailabilities,"Less AMI transferred from the EPI to the IT space than from the IT to the EPI compartment, with bioavailabilities of 1.3% and 55%, respectively.","Population Pharmacokinetics of Amitriptyline After Intrathecal, Epidural, and Intravenous Administration in Sheep. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26469370/),%,1.3,108406,DB00321,Amitriptyline
,26469370,bioavailabilities,"Less AMI transferred from the EPI to the IT space than from the IT to the EPI compartment, with bioavailabilities of 1.3% and 55%, respectively.","Population Pharmacokinetics of Amitriptyline After Intrathecal, Epidural, and Intravenous Administration in Sheep. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26469370/),%,55,108407,DB00321,Amitriptyline
,2109680,plasma,"In the second group, addition of valpromide resulted in a significant increase of antidepressant plasma levels: from 70.5 +/- 35 to 105.5 +/- 49 ng/ml (p less than 0.0003) for amitriptyline, and from 61.0 +/- 34 to 100.5 +/- 65 ng/ml (p less than 0.01) for nortriptyline.",[Valpromide-amitriptyline interaction. Increase in the bioavailability of amitriptyline and nortriptyline caused by valpromide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109680/),ng,70,113444,DB00321,Amitriptyline
,2109680,plasma,"In the second group, addition of valpromide resulted in a significant increase of antidepressant plasma levels: from 70.5 +/- 35 to 105.5 +/- 49 ng/ml (p less than 0.0003) for amitriptyline, and from 61.0 +/- 34 to 100.5 +/- 65 ng/ml (p less than 0.01) for nortriptyline.",[Valpromide-amitriptyline interaction. Increase in the bioavailability of amitriptyline and nortriptyline caused by valpromide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109680/),ng,105,113445,DB00321,Amitriptyline
,2109680,plasma,"In the second group, addition of valpromide resulted in a significant increase of antidepressant plasma levels: from 70.5 +/- 35 to 105.5 +/- 49 ng/ml (p less than 0.0003) for amitriptyline, and from 61.0 +/- 34 to 100.5 +/- 65 ng/ml (p less than 0.01) for nortriptyline.",[Valpromide-amitriptyline interaction. Increase in the bioavailability of amitriptyline and nortriptyline caused by valpromide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109680/),ng,61.0,113446,DB00321,Amitriptyline
,2109680,plasma,"In the second group, addition of valpromide resulted in a significant increase of antidepressant plasma levels: from 70.5 +/- 35 to 105.5 +/- 49 ng/ml (p less than 0.0003) for amitriptyline, and from 61.0 +/- 34 to 100.5 +/- 65 ng/ml (p less than 0.01) for nortriptyline.",[Valpromide-amitriptyline interaction. Increase in the bioavailability of amitriptyline and nortriptyline caused by valpromide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109680/),ng,100.5,113447,DB00321,Amitriptyline
,1570375,renal plasma clearance,The renal plasma clearance of AT-NO varied between 75 and 265 ml/min in the six volunteers.,Urinary metabolites of amitriptylinoxide and amitriptyline in single-dose experiments and during continuous therapy. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1570375/),[ml] / [min],75 and 265,116255,DB00321,Amitriptyline
,25308868,C(max),"The C(max), AUC(last), and AUC(0-∞) of amitriptyline hydrochloride 10 mg were 5.96 ng/mL, 91.35 ng·h/mL and 109.74 ng·h/mL, respectively.","Single-dose, randomized, open-label, 2-way crossover study of the pharmacokinetics of amitriptyline hydrochloride 10- and 25-mg tablet in healthy male Korean volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25308868/),[ng] / [ml],5.96,116968,DB00321,Amitriptyline
,25308868,AUC(last),"The C(max), AUC(last), and AUC(0-∞) of amitriptyline hydrochloride 10 mg were 5.96 ng/mL, 91.35 ng·h/mL and 109.74 ng·h/mL, respectively.","Single-dose, randomized, open-label, 2-way crossover study of the pharmacokinetics of amitriptyline hydrochloride 10- and 25-mg tablet in healthy male Korean volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25308868/),[h·ng] / [ml],91.35,116969,DB00321,Amitriptyline
,25308868,AUC(0-∞),"The C(max), AUC(last), and AUC(0-∞) of amitriptyline hydrochloride 10 mg were 5.96 ng/mL, 91.35 ng·h/mL and 109.74 ng·h/mL, respectively.","Single-dose, randomized, open-label, 2-way crossover study of the pharmacokinetics of amitriptyline hydrochloride 10- and 25-mg tablet in healthy male Korean volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25308868/),[h·ng] / [ml],109.74,116970,DB00321,Amitriptyline
,25308868,C(max),"The C(max), AUC(last), and AUC(0-∞) of amitriptyline hydrochloride 25 mg were 17.69 ng/mL, 260.68 ng·h/mL, and 296.87 ng·h/mL, respectively.","Single-dose, randomized, open-label, 2-way crossover study of the pharmacokinetics of amitriptyline hydrochloride 10- and 25-mg tablet in healthy male Korean volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25308868/),[ng] / [ml],17.69,116971,DB00321,Amitriptyline
,25308868,AUC(last),"The C(max), AUC(last), and AUC(0-∞) of amitriptyline hydrochloride 25 mg were 17.69 ng/mL, 260.68 ng·h/mL, and 296.87 ng·h/mL, respectively.","Single-dose, randomized, open-label, 2-way crossover study of the pharmacokinetics of amitriptyline hydrochloride 10- and 25-mg tablet in healthy male Korean volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25308868/),[h·ng] / [ml],260.68,116972,DB00321,Amitriptyline
,25308868,AUC(0-∞),"The C(max), AUC(last), and AUC(0-∞) of amitriptyline hydrochloride 25 mg were 17.69 ng/mL, 260.68 ng·h/mL, and 296.87 ng·h/mL, respectively.","Single-dose, randomized, open-label, 2-way crossover study of the pharmacokinetics of amitriptyline hydrochloride 10- and 25-mg tablet in healthy male Korean volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25308868/),[h·ng] / [ml],296.87,116973,DB00321,Amitriptyline
,2255664,Run time,Run time was approximately 14 min.,An automated method for the determination of nortriptyline and its isomeric 10-hydroxylated metabolites in plasma by high pressure liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2255664/),min,14,117067,DB00321,Amitriptyline
,2255664,flow,"5 mu 250 x 4.6 mm column, a mobile phase consisting of aqueous ammonium: methanol: acetonitrile (0.8:6.2:93, v/v), and flow of 1.3 ml/min.",An automated method for the determination of nortriptyline and its isomeric 10-hydroxylated metabolites in plasma by high pressure liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2255664/),[ml] / [min],1.3,117068,DB00321,Amitriptyline
,8436164,plasma ratio,"There was only a minor pharmacokinetic interaction between amitriptyline (AMT) and toloxatone, with a small increase in the AMT/NT (nortriptyline) plasma ratio: 0.68 before and 0.78 after toloxatone.",Minor and clinically non-significant interaction between toloxatone and amitriptyline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436164/),,0.68,125236,DB00321,Amitriptyline
,8436164,plasma ratio,"There was only a minor pharmacokinetic interaction between amitriptyline (AMT) and toloxatone, with a small increase in the AMT/NT (nortriptyline) plasma ratio: 0.68 before and 0.78 after toloxatone.",Minor and clinically non-significant interaction between toloxatone and amitriptyline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436164/),,0.78,125237,DB00321,Amitriptyline
,6808544,free fraction,The free fraction of OHNT in plasma of healthy subjects was about 35%.,Antidepressive effect and pharmacokinetics of amitriptyline with consideration of unbound drug and 10-hydroxynortriptyline plasma levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6808544/),%,35,126579,DB00321,Amitriptyline
,24151591,AUC,"Cyclobenzaprine plasma profiles for the reference and test products were similar, as well as absorption pharmacokinetic parameters AUC (reference: 199.4 ng ∗ h/mL; test: 201.6 ng ∗ h/mL), Cmax (reference: 7.0 ng/mL; test: 7.2 ng/mL), and T(max) (reference: 4.5 h; test: 4.6 h).",Pharmacokinetics and bioequivalence evaluation of cyclobenzaprine tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24151591/),[h·ng·∗] / [ml],199.4,132396,DB00321,Amitriptyline
,24151591,AUC,"Cyclobenzaprine plasma profiles for the reference and test products were similar, as well as absorption pharmacokinetic parameters AUC (reference: 199.4 ng ∗ h/mL; test: 201.6 ng ∗ h/mL), Cmax (reference: 7.0 ng/mL; test: 7.2 ng/mL), and T(max) (reference: 4.5 h; test: 4.6 h).",Pharmacokinetics and bioequivalence evaluation of cyclobenzaprine tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24151591/),[h·ng·∗] / [ml],201.6,132397,DB00321,Amitriptyline
,24151591,Cmax,"Cyclobenzaprine plasma profiles for the reference and test products were similar, as well as absorption pharmacokinetic parameters AUC (reference: 199.4 ng ∗ h/mL; test: 201.6 ng ∗ h/mL), Cmax (reference: 7.0 ng/mL; test: 7.2 ng/mL), and T(max) (reference: 4.5 h; test: 4.6 h).",Pharmacokinetics and bioequivalence evaluation of cyclobenzaprine tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24151591/),[ng] / [ml],7.0,132398,DB00321,Amitriptyline
,24151591,Cmax,"Cyclobenzaprine plasma profiles for the reference and test products were similar, as well as absorption pharmacokinetic parameters AUC (reference: 199.4 ng ∗ h/mL; test: 201.6 ng ∗ h/mL), Cmax (reference: 7.0 ng/mL; test: 7.2 ng/mL), and T(max) (reference: 4.5 h; test: 4.6 h).",Pharmacokinetics and bioequivalence evaluation of cyclobenzaprine tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24151591/),[ng] / [ml],7.2,132399,DB00321,Amitriptyline
,24151591,T(max),"Cyclobenzaprine plasma profiles for the reference and test products were similar, as well as absorption pharmacokinetic parameters AUC (reference: 199.4 ng ∗ h/mL; test: 201.6 ng ∗ h/mL), Cmax (reference: 7.0 ng/mL; test: 7.2 ng/mL), and T(max) (reference: 4.5 h; test: 4.6 h).",Pharmacokinetics and bioequivalence evaluation of cyclobenzaprine tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24151591/),h,4.5,132400,DB00321,Amitriptyline
,24151591,T(max),"Cyclobenzaprine plasma profiles for the reference and test products were similar, as well as absorption pharmacokinetic parameters AUC (reference: 199.4 ng ∗ h/mL; test: 201.6 ng ∗ h/mL), Cmax (reference: 7.0 ng/mL; test: 7.2 ng/mL), and T(max) (reference: 4.5 h; test: 4.6 h).",Pharmacokinetics and bioequivalence evaluation of cyclobenzaprine tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24151591/),h,4.6,132401,DB00321,Amitriptyline
,24151591,rapid,Cyclobenzaprine pharmacokinetics can be described by a multicompartment open model with an average rapid elimination half-life (t(1/2)β) of 3.1 hours and an average terminal elimination half-life (t(1/2)γ) of 31.9 hours.,Pharmacokinetics and bioequivalence evaluation of cyclobenzaprine tablets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24151591/),h,3.1,132402,DB00321,Amitriptyline
,24151591,elimination half-life (t(1/2)β),Cyclobenzaprine pharmacokinetics can be described by a multicompartment open model with an average rapid elimination half-life (t(1/2)β) of 3.1 hours and an average terminal elimination half-life (t(1/2)γ) of 31.9 hours.,Pharmacokinetics and bioequivalence evaluation of cyclobenzaprine tablets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24151591/),h,3.1,132403,DB00321,Amitriptyline
,24151591,terminal elimination half-life (t(1/2)γ),Cyclobenzaprine pharmacokinetics can be described by a multicompartment open model with an average rapid elimination half-life (t(1/2)β) of 3.1 hours and an average terminal elimination half-life (t(1/2)γ) of 31.9 hours.,Pharmacokinetics and bioequivalence evaluation of cyclobenzaprine tablets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24151591/),h,31.9,132404,DB00321,Amitriptyline
,711927,Peak amitriptyline plasma concentrations,Peak amitriptyline plasma concentrations ranged from 10.8 to 43.7 ng/ml.,Contribution to the pharmacokinetics of amitriptyline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/711927/),[ng] / [ml],10.8 to 43.7,143143,DB00321,Amitriptyline
,711927,elimination half-life,The mean elimination half-life was 36.1 hours.,Contribution to the pharmacokinetics of amitriptyline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/711927/),h,36.1,143144,DB00321,Amitriptyline
,711927,first-pass metabolism,The mean estimated first-pass metabolism of amitriptyline was 60 per cent.,Contribution to the pharmacokinetics of amitriptyline. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/711927/),%,60,143145,DB00321,Amitriptyline
,711927,peak concentrations,"Significant quantities of the metabolite, nortriptyline, were produced although peak concentrations ranged from only 5.9 to 12.3 ng/ml.",Contribution to the pharmacokinetics of amitriptyline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/711927/),[ng] / [ml],5.9 to 12.3,143146,DB00321,Amitriptyline
,19754244,recovery,In vivo retrodialysis recovery was 89 +/- 2%.,Pharmacokinetics of amitriptyline in rabbit skin and plasma following iontophoretic administrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19754244/),%,89,144495,DB00321,Amitriptyline
,19754244,AUCs,"AMT skin exposure increased non-proportionally with current density: AUCs were 19 +/- 7, 119 +/- 56, and 615 +/- 302 mg/L/min for the 100, 200, and 300 muA/cm(2), respectively, and C(max) were 107 +/- 15, 1070 +/- 537, and 5870 +/- 1289 microg/L.",Pharmacokinetics of amitriptyline in rabbit skin and plasma following iontophoretic administrations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19754244/),[mg] / [l·min],19,144496,DB00321,Amitriptyline
,19754244,AUCs,"AMT skin exposure increased non-proportionally with current density: AUCs were 19 +/- 7, 119 +/- 56, and 615 +/- 302 mg/L/min for the 100, 200, and 300 muA/cm(2), respectively, and C(max) were 107 +/- 15, 1070 +/- 537, and 5870 +/- 1289 microg/L.",Pharmacokinetics of amitriptyline in rabbit skin and plasma following iontophoretic administrations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19754244/),[mg] / [l·min],119,144497,DB00321,Amitriptyline
,19754244,AUCs,"AMT skin exposure increased non-proportionally with current density: AUCs were 19 +/- 7, 119 +/- 56, and 615 +/- 302 mg/L/min for the 100, 200, and 300 muA/cm(2), respectively, and C(max) were 107 +/- 15, 1070 +/- 537, and 5870 +/- 1289 microg/L.",Pharmacokinetics of amitriptyline in rabbit skin and plasma following iontophoretic administrations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19754244/),[mg] / [l·min],615,144498,DB00321,Amitriptyline
,19754244,C(max),"AMT skin exposure increased non-proportionally with current density: AUCs were 19 +/- 7, 119 +/- 56, and 615 +/- 302 mg/L/min for the 100, 200, and 300 muA/cm(2), respectively, and C(max) were 107 +/- 15, 1070 +/- 537, and 5870 +/- 1289 microg/L.",Pharmacokinetics of amitriptyline in rabbit skin and plasma following iontophoretic administrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19754244/),[μg] / [l],107,144499,DB00321,Amitriptyline
,19754244,C(max),"AMT skin exposure increased non-proportionally with current density: AUCs were 19 +/- 7, 119 +/- 56, and 615 +/- 302 mg/L/min for the 100, 200, and 300 muA/cm(2), respectively, and C(max) were 107 +/- 15, 1070 +/- 537, and 5870 +/- 1289 microg/L.",Pharmacokinetics of amitriptyline in rabbit skin and plasma following iontophoretic administrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19754244/),[μg] / [l],1070,144500,DB00321,Amitriptyline
,19754244,C(max),"AMT skin exposure increased non-proportionally with current density: AUCs were 19 +/- 7, 119 +/- 56, and 615 +/- 302 mg/L/min for the 100, 200, and 300 muA/cm(2), respectively, and C(max) were 107 +/- 15, 1070 +/- 537, and 5870 +/- 1289 microg/L.",Pharmacokinetics of amitriptyline in rabbit skin and plasma following iontophoretic administrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19754244/),[μg] / [l],5870,144501,DB00321,Amitriptyline
,7424564,Clearance,"Clearance values of 135--185 and 190--200 ml/min were obtained for amitriptyline and nortriptyline, respectively.",Hemoperfusion with Amberlite resin in the treatment of self-poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7424564/),[ml] / [min],135--185,147714,DB00321,Amitriptyline
,7424564,Clearance,"Clearance values of 135--185 and 190--200 ml/min were obtained for amitriptyline and nortriptyline, respectively.",Hemoperfusion with Amberlite resin in the treatment of self-poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7424564/),[ml] / [min],190,147715,DB00321,Amitriptyline
,7424564,clearance,A clearance of 140 ml/min was obtained in a uremic patient with AV block II due to digitoxin intoxication.,Hemoperfusion with Amberlite resin in the treatment of self-poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7424564/),[ml] / [min],140,147716,DB00321,Amitriptyline
,6825390,systemic clearance,The mean systemic clearance did not change with age (10.8 +/- 2.1 ml/min/kg in elderly and 12.5 +/- 2.3 ml/min/kg in young subjects).,Amitriptyline disposition in young and elderly normal men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825390/),[ml] / [kg·min],10.8,148964,DB00321,Amitriptyline
,6825390,systemic clearance,The mean systemic clearance did not change with age (10.8 +/- 2.1 ml/min/kg in elderly and 12.5 +/- 2.3 ml/min/kg in young subjects).,Amitriptyline disposition in young and elderly normal men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825390/),[ml] / [kg·min],12.5,148965,DB00321,Amitriptyline
,6825390,t 1/2,Mean t 1/2 was longer in the older (21.7 +/- 2.9 hr) than in the younger group (16.2 +/- 6.1 hr) as a result of an increase in the volume of distribution (17.1 +/- 2.4 and 14.1 +/- 2.0 l/kg).,Amitriptyline disposition in young and elderly normal men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825390/),h,21.7,148966,DB00321,Amitriptyline
,6825390,t 1/2,Mean t 1/2 was longer in the older (21.7 +/- 2.9 hr) than in the younger group (16.2 +/- 6.1 hr) as a result of an increase in the volume of distribution (17.1 +/- 2.4 and 14.1 +/- 2.0 l/kg).,Amitriptyline disposition in young and elderly normal men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825390/),h,16.2,148967,DB00321,Amitriptyline
,6825390,volume of distribution,Mean t 1/2 was longer in the older (21.7 +/- 2.9 hr) than in the younger group (16.2 +/- 6.1 hr) as a result of an increase in the volume of distribution (17.1 +/- 2.4 and 14.1 +/- 2.0 l/kg).,Amitriptyline disposition in young and elderly normal men. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825390/),[l] / [kg],17.1,148968,DB00321,Amitriptyline
,6825390,volume of distribution,Mean t 1/2 was longer in the older (21.7 +/- 2.9 hr) than in the younger group (16.2 +/- 6.1 hr) as a result of an increase in the volume of distribution (17.1 +/- 2.4 and 14.1 +/- 2.0 l/kg).,Amitriptyline disposition in young and elderly normal men. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825390/),[l] / [kg],14.1,148969,DB00321,Amitriptyline
,20954218,recovery,"The recovery was 85.3, 88.4 and 80.7% for amitriptyline, nortriptyline and doxepin respectively.",Development and validation of amitriptyline and its metabolite in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954218/),%,85.3,154839,DB00321,Amitriptyline
,20954218,recovery,"The recovery was 85.3, 88.4 and 80.7% for amitriptyline, nortriptyline and doxepin respectively.",Development and validation of amitriptyline and its metabolite in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954218/),%,88.4,154840,DB00321,Amitriptyline
,20954218,recovery,"The recovery was 85.3, 88.4 and 80.7% for amitriptyline, nortriptyline and doxepin respectively.",Development and validation of amitriptyline and its metabolite in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954218/),%,80.7,154841,DB00321,Amitriptyline
,20954218,Total run time,"Total run time was 1.2 min only for each sample, which makes it possible to analyze more than 400 samples per day.",Development and validation of amitriptyline and its metabolite in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954218/),min,1.2,154842,DB00321,Amitriptyline
,7203728,peak time,AMI was absorbed rather slowly (mean peak time 10.4 +/- 1.6 hrs) but very efficiently (F: 0.59-0.75).,Pharmacokinetics of amitriptyline in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7203728/),h,10.4,159198,DB00321,Amitriptyline
,7203728,F,AMI was absorbed rather slowly (mean peak time 10.4 +/- 1.6 hrs) but very efficiently (F: 0.59-0.75).,Pharmacokinetics of amitriptyline in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7203728/),,0.59-0.75,159199,DB00321,Amitriptyline
,7203728,appearance clearance,The rate of formation of nortriptyline (NT) as well as the appearance clearance values (0.18-0.45 l/h/kg) of AMI were significantly lower than those previously described for younger subjects.,Pharmacokinetics of amitriptyline in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7203728/),[l] / [h·kg],0.18-0.45,159200,DB00321,Amitriptyline
,976307,biological half-life,"The calculated biological half-life of amitriptyline was about 17 hours, a figure which differs considerably from previously calculated values for volunteers, but is in accordance with some newer results from patients.",Pharmacokinetics of amitriptyline infused intravenously in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/976307/),h,17,160992,DB00321,Amitriptyline
,29138563,Ka,"The results of isothermal titration calorimetry demonstrated greater interaction of amitriptyline with the surface of anionic squarticles (Ka =28,700) than with cationic ones (Ka =5,010).",Squarticles as the nanoantidotes to sequester the overdosed antidepressant for detoxification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138563/),,"28,700",161147,DB00321,Amitriptyline
,29138563,Ka,"The results of isothermal titration calorimetry demonstrated greater interaction of amitriptyline with the surface of anionic squarticles (Ka =28,700) than with cationic ones (Ka =5,010).",Squarticles as the nanoantidotes to sequester the overdosed antidepressant for detoxification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138563/),,"5,010",161148,DB00321,Amitriptyline
,7082776,bioavailability,"Based on area calculations, the bioavailability of the 10 mg oral tablet, 10 mg i.m. and 20 mg i.m. injection was 0.33, 0.76, and 0.56, respectively, when compared to the 10 mg i.v. injection of cyclobenzaprine hydrochloride.",Evidence for route dependent biotransformation of cyclobenzaprine hydrochloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7082776/),,0.33,161244,DB00321,Amitriptyline
,7082776,bioavailability,"Based on area calculations, the bioavailability of the 10 mg oral tablet, 10 mg i.m. and 20 mg i.m. injection was 0.33, 0.76, and 0.56, respectively, when compared to the 10 mg i.v. injection of cyclobenzaprine hydrochloride.",Evidence for route dependent biotransformation of cyclobenzaprine hydrochloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7082776/),,0.76,161245,DB00321,Amitriptyline
,7082776,bioavailability,"Based on area calculations, the bioavailability of the 10 mg oral tablet, 10 mg i.m. and 20 mg i.m. injection was 0.33, 0.76, and 0.56, respectively, when compared to the 10 mg i.v. injection of cyclobenzaprine hydrochloride.",Evidence for route dependent biotransformation of cyclobenzaprine hydrochloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7082776/),,0.56,161246,DB00321,Amitriptyline
,1711447,elimination half-life,Its elimination half-life of 33 hours permits once daily oral administration.,"Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1711447/),h,33,167736,DB00321,Amitriptyline
,18780336,absolute oral bioavalability (F),"After oral administration of amitriptyline, approximately 1.50% of the dose was not absorbed, the extent of absolute oral bioavalability (F) was approximately 6.30%, and the hepatic and intestinal first-pass effects of amitriptyline were approximately 9% and 87% of the oral dose, respectively.","Pharmacokinetics of amitriptyline and one of its metabolites, nortriptyline, in rats: little contribution of considerable hepatic first-pass effect to low bioavailability of amitriptyline due to great intestinal first-pass effect. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18780336/),%,6.30,168296,DB00321,Amitriptyline
,18780336,first-pass effects,"After oral administration of amitriptyline, approximately 1.50% of the dose was not absorbed, the extent of absolute oral bioavalability (F) was approximately 6.30%, and the hepatic and intestinal first-pass effects of amitriptyline were approximately 9% and 87% of the oral dose, respectively.","Pharmacokinetics of amitriptyline and one of its metabolites, nortriptyline, in rats: little contribution of considerable hepatic first-pass effect to low bioavailability of amitriptyline due to great intestinal first-pass effect. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18780336/),%,9,168297,DB00321,Amitriptyline
,18780336,first-pass effects,"After oral administration of amitriptyline, approximately 1.50% of the dose was not absorbed, the extent of absolute oral bioavalability (F) was approximately 6.30%, and the hepatic and intestinal first-pass effects of amitriptyline were approximately 9% and 87% of the oral dose, respectively.","Pharmacokinetics of amitriptyline and one of its metabolites, nortriptyline, in rats: little contribution of considerable hepatic first-pass effect to low bioavailability of amitriptyline due to great intestinal first-pass effect. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18780336/),%,87,168298,DB00321,Amitriptyline
,18780336,F,The lower F value of amitriptyline in rats than that in humans (46 +/- 48%) was due to grater metabolism of amitriptyline in rats' liver and/or small intestine.,"Pharmacokinetics of amitriptyline and one of its metabolites, nortriptyline, in rats: little contribution of considerable hepatic first-pass effect to low bioavailability of amitriptyline due to great intestinal first-pass effect. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18780336/),%,46,168299,DB00321,Amitriptyline
,7751409,steady-state concentrations (Css),"The means and (SEM) of the steady-state concentrations (Css) of AMI, NTRIP, FLU, and NFLU were 80.6 (14.2), 52.6 (10.3), 85.3 (16.1), and 90 (13.6) ng/mL, respectively, and the apparent oral clearances (CLor) of AMI and FLU were 42.4 (8.6) and 14.9 (2.5) L/hr, respectively.",Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751409/),[ng] / [ml],80.6,168463,DB00321,Amitriptyline
,7751409,steady-state concentrations (Css),"The means and (SEM) of the steady-state concentrations (Css) of AMI, NTRIP, FLU, and NFLU were 80.6 (14.2), 52.6 (10.3), 85.3 (16.1), and 90 (13.6) ng/mL, respectively, and the apparent oral clearances (CLor) of AMI and FLU were 42.4 (8.6) and 14.9 (2.5) L/hr, respectively.",Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751409/),[ng] / [ml],52.6,168464,DB00321,Amitriptyline
,7751409,steady-state concentrations (Css),"The means and (SEM) of the steady-state concentrations (Css) of AMI, NTRIP, FLU, and NFLU were 80.6 (14.2), 52.6 (10.3), 85.3 (16.1), and 90 (13.6) ng/mL, respectively, and the apparent oral clearances (CLor) of AMI and FLU were 42.4 (8.6) and 14.9 (2.5) L/hr, respectively.",Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751409/),[ng] / [ml],85.3,168465,DB00321,Amitriptyline
,7751409,steady-state concentrations (Css),"The means and (SEM) of the steady-state concentrations (Css) of AMI, NTRIP, FLU, and NFLU were 80.6 (14.2), 52.6 (10.3), 85.3 (16.1), and 90 (13.6) ng/mL, respectively, and the apparent oral clearances (CLor) of AMI and FLU were 42.4 (8.6) and 14.9 (2.5) L/hr, respectively.",Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751409/),[ng] / [ml],90,168466,DB00321,Amitriptyline
,7751409,apparent oral clearances (CLor),"The means and (SEM) of the steady-state concentrations (Css) of AMI, NTRIP, FLU, and NFLU were 80.6 (14.2), 52.6 (10.3), 85.3 (16.1), and 90 (13.6) ng/mL, respectively, and the apparent oral clearances (CLor) of AMI and FLU were 42.4 (8.6) and 14.9 (2.5) L/hr, respectively.",Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751409/),[l] / [h],42.4,168467,DB00321,Amitriptyline
,7751409,apparent oral clearances (CLor),"The means and (SEM) of the steady-state concentrations (Css) of AMI, NTRIP, FLU, and NFLU were 80.6 (14.2), 52.6 (10.3), 85.3 (16.1), and 90 (13.6) ng/mL, respectively, and the apparent oral clearances (CLor) of AMI and FLU were 42.4 (8.6) and 14.9 (2.5) L/hr, respectively.",Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751409/),[l] / [h],14.9,168468,DB00321,Amitriptyline
,7751409,steady-state concentration ratio (Css(m)/Css),The metabolite/drug steady-state concentration ratio (Css(m)/Css) for NTRIP/AMI was 0.75 (0.14) and for NFLU/FLU was 1.27 (0.17).,Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751409/),,0.75,168469,DB00321,Amitriptyline
,7751409,steady-state concentration ratio (Css(m)/Css),The metabolite/drug steady-state concentration ratio (Css(m)/Css) for NTRIP/AMI was 0.75 (0.14) and for NFLU/FLU was 1.27 (0.17).,Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751409/),,1.27,168470,DB00321,Amitriptyline
,22120786,m/z,The ion-pairs including m/z 276.2-216.2 for cyclobenzaprine and m/z 325.2-109.1 for IS were used for monitoring.,Determination of cyclobenzaprine in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22120786/),,276.2-216.2,169106,DB00321,Amitriptyline
,22120786,m/z,The ion-pairs including m/z 276.2-216.2 for cyclobenzaprine and m/z 325.2-109.1 for IS were used for monitoring.,Determination of cyclobenzaprine in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22120786/),,325.2-109.1,169107,DB00321,Amitriptyline
,20570077,flow rate,"Chromatographic separation was performed on a XB-C4 column (4.6 mm x 250 mm, 5 microm, Welch Materials) with a mobile phase consisting of 10mM ammonium acetate (0.6 per thousand formic acid)-acetonitrile (60:40, v/v) at a flow rate of 1.0 ml/min.",Validated LC-MS (ESI) assay for the simultaneous determination of amitriptyline and its metabolite nortriptyline in rat plasma: application to a pharmacokinetic comparison. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20570077/),[ml] / [min],1.0,174468,DB00321,Amitriptyline
,3971637,plasma clearances,"The mean plasma clearances of carbamazepine were 19.8, 54.6 and 113.3 ml/h/kg in groups 1, 2 and 3, respectively.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),[ml] / [h·kg],19.8,176121,DB00321,Amitriptyline
,3971637,plasma clearances,"The mean plasma clearances of carbamazepine were 19.8, 54.6 and 113.3 ml/h/kg in groups 1, 2 and 3, respectively.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),[ml] / [h·kg],54.6,176122,DB00321,Amitriptyline
,3971637,plasma clearances,"The mean plasma clearances of carbamazepine were 19.8, 54.6 and 113.3 ml/h/kg in groups 1, 2 and 3, respectively.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),[ml] / [h·kg],113.3,176123,DB00321,Amitriptyline
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,1.9,176124,DB00321,Amitriptyline
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,3.3,176125,DB00321,Amitriptyline
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,4.0,176126,DB00321,Amitriptyline
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,23,176127,DB00321,Amitriptyline
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,32,176128,DB00321,Amitriptyline
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,24,176129,DB00321,Amitriptyline
,11583471,apparent oral clearance,The mean apparent oral clearance of amitriptyline in 8 human volunteers was decreased from 2791 ml/min in the control condition to 2069 ml/min with ketoconazole.,Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583471/),[ml] / [min],2791,176461,DB00321,Amitriptyline
,11583471,apparent oral clearance,The mean apparent oral clearance of amitriptyline in 8 human volunteers was decreased from 2791 ml/min in the control condition to 2069 ml/min with ketoconazole.,Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583471/),[ml] / [min],2069,176462,DB00321,Amitriptyline
,21369441,T(max),"Maximum concentration was observed at 6.5 h after administration in sham group with a concentration of 439.6 ng/ml, whereas in SCI group T(max) was at 2.7 h with a concentration of 2763.9 ng/ml.",Amitriptyline pharmacokinetics in experimental spinal cord injury in the rabbit. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21369441/),h,2.7,177469,DB00321,Amitriptyline
,21369441,T(max),"Maximum concentration was observed at 6.5 h after administration in sham group with a concentration of 439.6 ng/ml, whereas in SCI group T(max) was at 2.7 h with a concentration of 2763.9 ng/ml.",Amitriptyline pharmacokinetics in experimental spinal cord injury in the rabbit. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21369441/),[ng] / [ml],2763.9,177470,DB00321,Amitriptyline
,21369441,AUC,"In SCI group, AUC was 9465.6 ng.h/ml and half life was 6 h and for control group it was 2817.4 ng.h/ml and 6.4 h, respectively.",Amitriptyline pharmacokinetics in experimental spinal cord injury in the rabbit. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21369441/),[h·ng] / [ml],9465.6,177471,DB00321,Amitriptyline
,21369441,half life,"In SCI group, AUC was 9465.6 ng.h/ml and half life was 6 h and for control group it was 2817.4 ng.h/ml and 6.4 h, respectively.",Amitriptyline pharmacokinetics in experimental spinal cord injury in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21369441/),h,6,177472,DB00321,Amitriptyline
,21369441,half life,"In SCI group, AUC was 9465.6 ng.h/ml and half life was 6 h and for control group it was 2817.4 ng.h/ml and 6.4 h, respectively.",Amitriptyline pharmacokinetics in experimental spinal cord injury in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21369441/),[h·ng] / [ml],2817.4,177473,DB00321,Amitriptyline
,21369441,half life,"In SCI group, AUC was 9465.6 ng.h/ml and half life was 6 h and for control group it was 2817.4 ng.h/ml and 6.4 h, respectively.",Amitriptyline pharmacokinetics in experimental spinal cord injury in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21369441/),h,6.4,177474,DB00321,Amitriptyline
,8345006,flow rate,The chromatography was performed using a Microsorb-CN column; the mobile phase consisted of 85:15 methanol/0.005 M ammonium acetate buffer; flow rate of 1.6 ml/min; and ultraviolet detection at 254 nm.,High-performance liquid chromatographic determination of perphenazine in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8345006/),[ml] / [min],1.6,181651,DB00321,Amitriptyline
,8345006,Retention times,"Retention times were 10.8 and 18.1 min for perphenazine and amitriptyline HCl, respectively.",High-performance liquid chromatographic determination of perphenazine in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8345006/),min,10.8,181652,DB00321,Amitriptyline
,8345006,Retention times,"Retention times were 10.8 and 18.1 min for perphenazine and amitriptyline HCl, respectively.",High-performance liquid chromatographic determination of perphenazine in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8345006/),min,18.1,181653,DB00321,Amitriptyline
greater,8345006,recovery,The recovery of perphenazine added to plasma in the concentration range of 0.05-5 micrograms/ml was found to be greater than 80%.,High-performance liquid chromatographic determination of perphenazine in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8345006/),%,80,181654,DB00321,Amitriptyline
,1859509,maximum plasma levels,"The tests for the parent substance amitriptylinoxide revealed maximum plasma levels of 721 and 686 ng/ml at 1.96 h (i.v. infusion) and 0.82 h (oral formulation), respectively.",[Plasma and urine kinetics of amitriptyline oxide and its metabolites. Comparison of intravenous infusion and oral administration in volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1859509/),[ng] / [ml],721,190956,DB00321,Amitriptyline
,1859509,maximum plasma levels,"The tests for the parent substance amitriptylinoxide revealed maximum plasma levels of 721 and 686 ng/ml at 1.96 h (i.v. infusion) and 0.82 h (oral formulation), respectively.",[Plasma and urine kinetics of amitriptyline oxide and its metabolites. Comparison of intravenous infusion and oral administration in volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1859509/),[ng] / [ml],686,190957,DB00321,Amitriptyline
,1859509,area under the curve from time 0 to infinity AUC (0-infinity),Mean values of 2331 (infusion) and 1714 h.ng/ml (oral formulation) were determined for the area under the curve from time 0 to infinity AUC (0-infinity).,[Plasma and urine kinetics of amitriptyline oxide and its metabolites. Comparison of intravenous infusion and oral administration in volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1859509/),[h·ng] / [ml],2331,190958,DB00321,Amitriptyline
,1859509,area under the curve from time 0 to infinity AUC (0-infinity),Mean values of 2331 (infusion) and 1714 h.ng/ml (oral formulation) were determined for the area under the curve from time 0 to infinity AUC (0-infinity).,[Plasma and urine kinetics of amitriptyline oxide and its metabolites. Comparison of intravenous infusion and oral administration in volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1859509/),[h·ng] / [ml],1714,190959,DB00321,Amitriptyline
,10872574,peak blood concentrations,"The peak blood concentrations of AMT and NTR in Group I were 0.34 and 0.28 microg/mL, respectively, and those of AMT and NTR in Group II were 0.59 and 0.43 microg/mL, respectively, and were reached at 1 h after single oral administration.",Blood concentrations of amitriptyline and its metabolite in rats after acute oral administration of amitriptyline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872574/),[μg] / [ml],0.34,191279,DB00321,Amitriptyline
,10872574,peak blood concentrations,"The peak blood concentrations of AMT and NTR in Group I were 0.34 and 0.28 microg/mL, respectively, and those of AMT and NTR in Group II were 0.59 and 0.43 microg/mL, respectively, and were reached at 1 h after single oral administration.",Blood concentrations of amitriptyline and its metabolite in rats after acute oral administration of amitriptyline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872574/),[μg] / [ml],0.28,191280,DB00321,Amitriptyline
,10872574,peak blood concentrations,"The peak blood concentrations of AMT and NTR in Group I were 0.34 and 0.28 microg/mL, respectively, and those of AMT and NTR in Group II were 0.59 and 0.43 microg/mL, respectively, and were reached at 1 h after single oral administration.",Blood concentrations of amitriptyline and its metabolite in rats after acute oral administration of amitriptyline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872574/),[μg] / [ml],0.59,191281,DB00321,Amitriptyline
,10872574,peak blood concentrations,"The peak blood concentrations of AMT and NTR in Group I were 0.34 and 0.28 microg/mL, respectively, and those of AMT and NTR in Group II were 0.59 and 0.43 microg/mL, respectively, and were reached at 1 h after single oral administration.",Blood concentrations of amitriptyline and its metabolite in rats after acute oral administration of amitriptyline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872574/),[μg] / [ml],0.43,191282,DB00321,Amitriptyline
,11243492,TPTs,The TPTs of AMI and NOR were 81% and 62% of the freely diffusable antipyrine.,Transplacental transfer of amitriptyline and nortriptyline in isolated perfused human placenta. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11243492/),%,81,191715,DB00321,Amitriptyline
,11243492,TPTs,The TPTs of AMI and NOR were 81% and 62% of the freely diffusable antipyrine.,Transplacental transfer of amitriptyline and nortriptyline in isolated perfused human placenta. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11243492/),%,62,191716,DB00321,Amitriptyline
,32879225,activation energy (Ea),The degradation was a pseudo first-order reaction; activation energy (Ea) was 88.70 kJ/mol and activation entropy (ΔS) was -80.73 J/K·mol.,Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),[kj] / [mol],88.70,195214,DB00321,Amitriptyline
,32879225,activation entropy (ΔS),The degradation was a pseudo first-order reaction; activation energy (Ea) was 88.70 kJ/mol and activation entropy (ΔS) was -80.73 J/K·mol.,Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),[j] / [k·mol],-,195215,DB00321,Amitriptyline
,32879225,activation entropy (ΔS),The degradation was a pseudo first-order reaction; activation energy (Ea) was 88.70 kJ/mol and activation entropy (ΔS) was -80.73 J/K·mol.,Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),[j] / [k·mol],80.73,195216,DB00321,Amitriptyline
,32879225,retention times,"In the AMX degradation experiment, peaks considered to be degradation products A (I) and B (II) were detected at retention times of around 3 min and 30 min in LC/UV measurements, respectively.",Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),min,3,195217,DB00321,Amitriptyline
,32879225,retention times,"In the AMX degradation experiment, peaks considered to be degradation products A (I) and B (II) were detected at retention times of around 3 min and 30 min in LC/UV measurements, respectively.",Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),min,30,195218,DB00321,Amitriptyline
,7157460,lower detection limit,The lower detection limit was 2-5 ng/ml for both drugs.,A sensitive gas chromatographic assay for amitriptyline and nortriptyline in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7157460/),[ng] / [ml],2-5,197403,DB00321,Amitriptyline
,7157460,recovery,"The method is specific for AT and NT, with a recovery of AT and NT of 68 and 71%, respectively.",A sensitive gas chromatographic assay for amitriptyline and nortriptyline in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7157460/),%,68,197404,DB00321,Amitriptyline
,7157460,recovery,"The method is specific for AT and NT, with a recovery of AT and NT of 68 and 71%, respectively.",A sensitive gas chromatographic assay for amitriptyline and nortriptyline in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7157460/),%,71,197405,DB00321,Amitriptyline
,2389248,affinity constant,The intensity of this phenomenon was a function of both the antibody affinity constant (10(9) M-1) and the neutralizing capacity (varying from 0.005 to 0.2 mg/kg) of the circulating antibodies in each immunized rabbit.,The effect of nortriptyline-specific active immunization on amitriptyline toxicity and disposition in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2389248/),1/[M],10(9),198243,DB00321,Amitriptyline
,10383563,maximal plasma amitriptyline concentration Cmax,"Following dosing with OROS (amitriptyline hydrochloride), the mean maximal plasma amitriptyline concentration Cmax (15.3 ng ml-1 ) was lower and the mean tmax (25.7 h) was longer than that associated with the equivalent IR dose administered at nighttime (26.8 ng ml-1 and 6.3 h, respectively).",Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383563/),[ng] / [ml],15.3,199641,DB00321,Amitriptyline
,10383563,tmax,"Following dosing with OROS (amitriptyline hydrochloride), the mean maximal plasma amitriptyline concentration Cmax (15.3 ng ml-1 ) was lower and the mean tmax (25.7 h) was longer than that associated with the equivalent IR dose administered at nighttime (26.8 ng ml-1 and 6.3 h, respectively).",Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383563/),h,25.7,199642,DB00321,Amitriptyline
,10383563,tmax,"Following dosing with OROS (amitriptyline hydrochloride), the mean maximal plasma amitriptyline concentration Cmax (15.3 ng ml-1 ) was lower and the mean tmax (25.7 h) was longer than that associated with the equivalent IR dose administered at nighttime (26.8 ng ml-1 and 6.3 h, respectively).",Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383563/),[ng] / [ml],26.8,199643,DB00321,Amitriptyline
,10383563,tmax,"Following dosing with OROS (amitriptyline hydrochloride), the mean maximal plasma amitriptyline concentration Cmax (15.3 ng ml-1 ) was lower and the mean tmax (25.7 h) was longer than that associated with the equivalent IR dose administered at nighttime (26.8 ng ml-1 and 6.3 h, respectively).",Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383563/),h,6.3,199644,DB00321,Amitriptyline
,10383563,bioavailability,"The bioavailability of amitriptyline following OROS dosing was 95% relative to IR every 8 h dosing, and 89% relative to IR nighttime dosing.",Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383563/),%,95,199645,DB00321,Amitriptyline
,10383563,bioavailability,"The bioavailability of amitriptyline following OROS dosing was 95% relative to IR every 8 h dosing, and 89% relative to IR nighttime dosing.",Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383563/),%,89,199646,DB00321,Amitriptyline
,659530,sensitivity,"Using 1 ml of plasma, the sensitivity limit was 0.5 ng/ml for both substances.",Determination of amitriptyline and nortriptyline in human plasma by quantitative thin-layer chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/659530/),[ng] / [ml],0.5,204536,DB00321,Amitriptyline
,25683584,maximum plasma concentration (CMAX),The mean maximum plasma concentration (CMAX) of amitriptyline was 27.4 ng mL(-1) at 1 hour and its mean terminal half-life was 4.33 hours following oral amitriptyline.,Pharmacokinetics of intravenous and oral amitriptyline and its active metabolite nortriptyline in Greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25683584/),[ng] / [ml],27.4,208170,DB00321,Amitriptyline
,25683584,terminal half-life,The mean maximum plasma concentration (CMAX) of amitriptyline was 27.4 ng mL(-1) at 1 hour and its mean terminal half-life was 4.33 hours following oral amitriptyline.,Pharmacokinetics of intravenous and oral amitriptyline and its active metabolite nortriptyline in Greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25683584/),h,4.33,208171,DB00321,Amitriptyline
,25683584,Bioavailability,Bioavailability of oral amitriptyline was 6%.,Pharmacokinetics of intravenous and oral amitriptyline and its active metabolite nortriptyline in Greyhound dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25683584/),%,6,208172,DB00321,Amitriptyline
,25683584,CMAX,The mean CMAX of nortriptyline was 14.4 ng mL(-1) at 2.05 hours and its mean terminal half-life was 6.20 hours following oral amitriptyline.,Pharmacokinetics of intravenous and oral amitriptyline and its active metabolite nortriptyline in Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25683584/),[ng] / [ml],14.4,208173,DB00321,Amitriptyline
,25683584,terminal half-life,The mean CMAX of nortriptyline was 14.4 ng mL(-1) at 2.05 hours and its mean terminal half-life was 6.20 hours following oral amitriptyline.,Pharmacokinetics of intravenous and oral amitriptyline and its active metabolite nortriptyline in Greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25683584/),h,6.20,208174,DB00321,Amitriptyline
,28674244,unbound Ki,"Terbinafine competitively inhibited amitriptyline or nortriptyline E-10-hydroxylation, with unbound Ki values of 13.7 and 12.4 nM, respectively.",Analysis of the Mechanism of Prolonged Persistence of Drug Interaction between Terbinafine and Amitriptyline or Nortriptyline. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28674244/),nM,13.7,209869,DB00321,Amitriptyline
,28674244,unbound Ki,"Terbinafine competitively inhibited amitriptyline or nortriptyline E-10-hydroxylation, with unbound Ki values of 13.7 and 12.4 nM, respectively.",Analysis of the Mechanism of Prolonged Persistence of Drug Interaction between Terbinafine and Amitriptyline or Nortriptyline. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28674244/),nM,12.4,209870,DB00321,Amitriptyline
,19356393,relative bioavailability,"This formulation presented a 92.8% of relative bioavailability (IC 85.5 - 105%) and a significant reduction in Cmax (IC 58 - 65.5%), when compared with equal dose of the immediate release tablet.",Bioavailability of a controlled-release cyclobenzaprine tablet and influence of a high fat meal on bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19356393/),%,92.8,213247,DB00321,Amitriptyline
,19356393,IC,"This formulation presented a 92.8% of relative bioavailability (IC 85.5 - 105%) and a significant reduction in Cmax (IC 58 - 65.5%), when compared with equal dose of the immediate release tablet.",Bioavailability of a controlled-release cyclobenzaprine tablet and influence of a high fat meal on bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19356393/),%,85.5 - 105,213248,DB00321,Amitriptyline
,30564074,extraction recoveries,"Under the optimum experimental conditions, extraction recoveries and enrichment factors of the selected drugs ranged from 69-84 % and 345-420, respectively.",Determination of tricyclic antidepressants in human urine samples by the three-step sample pretreatment followed by HPLC-UV analysis: an efficient analytical method for further pharmacokinetic and forensic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30564074/),%,69-84,227547,DB00321,Amitriptyline
,30564074,enrichment factors,"Under the optimum experimental conditions, extraction recoveries and enrichment factors of the selected drugs ranged from 69-84 % and 345-420, respectively.",Determination of tricyclic antidepressants in human urine samples by the three-step sample pretreatment followed by HPLC-UV analysis: an efficient analytical method for further pharmacokinetic and forensic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30564074/),,345-420,227548,DB00321,Amitriptyline
,3621584,relative oral/intramuscular bioavailability,"The relative oral/intramuscular bioavailability of amitriptyline was only 13%, and the steady-state concentrations of this drug on four consecutive days were acutely subtherapeutic (i.e., 3.6, 3.7, 3.9, and 3.7 micrograms/L).",Decreased drug absorption in a patient with Behçet's syndrome. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621584/),%,13,237079,DB00321,Amitriptyline
,3621584,steady-state concentrations,"The relative oral/intramuscular bioavailability of amitriptyline was only 13%, and the steady-state concentrations of this drug on four consecutive days were acutely subtherapeutic (i.e., 3.6, 3.7, 3.9, and 3.7 micrograms/L).",Decreased drug absorption in a patient with Behçet's syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621584/),μ,3.6,237080,DB00321,Amitriptyline
,3621584,steady-state concentrations,"The relative oral/intramuscular bioavailability of amitriptyline was only 13%, and the steady-state concentrations of this drug on four consecutive days were acutely subtherapeutic (i.e., 3.6, 3.7, 3.9, and 3.7 micrograms/L).",Decreased drug absorption in a patient with Behçet's syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621584/),μ,3.7,237081,DB00321,Amitriptyline
,3621584,steady-state concentrations,"The relative oral/intramuscular bioavailability of amitriptyline was only 13%, and the steady-state concentrations of this drug on four consecutive days were acutely subtherapeutic (i.e., 3.6, 3.7, 3.9, and 3.7 micrograms/L).",Decreased drug absorption in a patient with Behçet's syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621584/),μ,3.9,237082,DB00321,Amitriptyline
,32339314,maximum plasma concentration (Cmax ),"The mean maximum plasma concentration (Cmax ) of amitriptyline was 30.7 ng/ml, time to maximum plasma concentration (Tmax ) 1-2 hr, elimination half-life (t1/2 ) 17.2 hr, area under plasma concentration-time curve (AUC) 487.4 ng ml-1 hr-1 , apparent clearance (Cl/F) 2.6 L hr-1 kg-1 , and apparent volume of distribution (Vd/F) 60.1 L/kg.",Pharmacokinetic study of oral amitriptyline in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32339314/),[ng] / [ml],30.7,250218,DB00321,Amitriptyline
,32339314,time to maximum plasma concentration (Tmax ),"The mean maximum plasma concentration (Cmax ) of amitriptyline was 30.7 ng/ml, time to maximum plasma concentration (Tmax ) 1-2 hr, elimination half-life (t1/2 ) 17.2 hr, area under plasma concentration-time curve (AUC) 487.4 ng ml-1 hr-1 , apparent clearance (Cl/F) 2.6 L hr-1 kg-1 , and apparent volume of distribution (Vd/F) 60.1 L/kg.",Pharmacokinetic study of oral amitriptyline in horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32339314/),h,1-2,250219,DB00321,Amitriptyline
,32339314,elimination half-life (t1/2 ),"The mean maximum plasma concentration (Cmax ) of amitriptyline was 30.7 ng/ml, time to maximum plasma concentration (Tmax ) 1-2 hr, elimination half-life (t1/2 ) 17.2 hr, area under plasma concentration-time curve (AUC) 487.4 ng ml-1 hr-1 , apparent clearance (Cl/F) 2.6 L hr-1 kg-1 , and apparent volume of distribution (Vd/F) 60.1 L/kg.",Pharmacokinetic study of oral amitriptyline in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32339314/),h,17.2,250220,DB00321,Amitriptyline
,32339314,area under plasma concentration-time curve (AUC),"The mean maximum plasma concentration (Cmax ) of amitriptyline was 30.7 ng/ml, time to maximum plasma concentration (Tmax ) 1-2 hr, elimination half-life (t1/2 ) 17.2 hr, area under plasma concentration-time curve (AUC) 487.4 ng ml-1 hr-1 , apparent clearance (Cl/F) 2.6 L hr-1 kg-1 , and apparent volume of distribution (Vd/F) 60.1 L/kg.",Pharmacokinetic study of oral amitriptyline in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32339314/),[ng] / [h·ml],487.4,250221,DB00321,Amitriptyline
,32339314,apparent clearance (Cl/F),"The mean maximum plasma concentration (Cmax ) of amitriptyline was 30.7 ng/ml, time to maximum plasma concentration (Tmax ) 1-2 hr, elimination half-life (t1/2 ) 17.2 hr, area under plasma concentration-time curve (AUC) 487.4 ng ml-1 hr-1 , apparent clearance (Cl/F) 2.6 L hr-1 kg-1 , and apparent volume of distribution (Vd/F) 60.1 L/kg.",Pharmacokinetic study of oral amitriptyline in horses. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32339314/),[l] / [h·kg],2.6,250222,DB00321,Amitriptyline
,32339314,apparent volume of distribution (Vd/F),"The mean maximum plasma concentration (Cmax ) of amitriptyline was 30.7 ng/ml, time to maximum plasma concentration (Tmax ) 1-2 hr, elimination half-life (t1/2 ) 17.2 hr, area under plasma concentration-time curve (AUC) 487.4 ng ml-1 hr-1 , apparent clearance (Cl/F) 2.6 L hr-1 kg-1 , and apparent volume of distribution (Vd/F) 60.1 L/kg.",Pharmacokinetic study of oral amitriptyline in horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32339314/),[l] / [kg],60.1,250223,DB00321,Amitriptyline
,6707156,lower limit of detection,The lower limit of detection was 2 ng/ml for all compounds except 5 ng/ml for 10-OH-NT.,Gas chromatographic--mass spectrometric determination of amitriptyline and its major metabolites in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707156/),[ng] / [ml],2,251030,DB00321,Amitriptyline
,6707156,lower limit of detection,The lower limit of detection was 2 ng/ml for all compounds except 5 ng/ml for 10-OH-NT.,Gas chromatographic--mass spectrometric determination of amitriptyline and its major metabolites in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707156/),[ng] / [ml],5,251031,DB00321,Amitriptyline
,413141,beta-phase half-life,"Plasma levels peak at 2 h with a median level of 11.0 ng/ml, a median beta-phase half-life of 10.0 h, and a median apparent volume of distribution of 3.3 X 10(3) 1.","EEG, blood level, and behavioral effects of the antidepressant mianserin (ORG GB-94). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/413141/),h,10.0,252337,DB00321,Amitriptyline
,413141,apparent volume of distribution,"Plasma levels peak at 2 h with a median level of 11.0 ng/ml, a median beta-phase half-life of 10.0 h, and a median apparent volume of distribution of 3.3 X 10(3) 1.","EEG, blood level, and behavioral effects of the antidepressant mianserin (ORG GB-94). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/413141/),1,3.3 X 10(3),252338,DB00321,Amitriptyline
,30452773,metabolic clearance,"The biotransformation of amitriptyline into nortriptyline was significantly different between subjects with the CYP2C19*2/*2, *2/*3, and *3/*3 genotypes and those with the other genotypes, with an estimated metabolic clearance of 17 and 61.5 L/h, respectively.","Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30452773/),[l] / [h],17,261466,DB00321,Amitriptyline
,30452773,metabolic clearance,"The biotransformation of amitriptyline into nortriptyline was significantly different between subjects with the CYP2C19*2/*2, *2/*3, and *3/*3 genotypes and those with the other genotypes, with an estimated metabolic clearance of 17 and 61.5 L/h, respectively.","Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30452773/),[l] / [h],61.5,261467,DB00321,Amitriptyline
,30452773,Clearance,"Clearance of amitriptyline through pathways other than biotransformation into nortriptyline was estimated as 18.8 and 30.6 L/h for subjects with the CYP2D6*10/*10 and *10/*5 genotypes and those with the other genotypes, respectively.","Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30452773/),[l] / [h],18.8,261468,DB00321,Amitriptyline
,30452773,Clearance,"Clearance of amitriptyline through pathways other than biotransformation into nortriptyline was estimated as 18.8 and 30.6 L/h for subjects with the CYP2D6*10/*10 and *10/*5 genotypes and those with the other genotypes, respectively.","Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30452773/),[l] / [h],30.6,261469,DB00321,Amitriptyline
,19243207,t(lag),"No appreciable differences in the shape of the mean plasma cyclobenzaprine concentration versus time profile, t(lag) (2 hours) or t(max) (fed: 8 hours; fasted: 6 hours) were noted for CER 30 mg in the fed and fasted states.","Effect of food on the pharmacokinetics of once-daily cyclobenzaprine extended-release 30 mg: a randomized, open-label, crossover, single-centre study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19243207/),h,2,262090,DB00321,Amitriptyline
,19243207,t(max),"No appreciable differences in the shape of the mean plasma cyclobenzaprine concentration versus time profile, t(lag) (2 hours) or t(max) (fed: 8 hours; fasted: 6 hours) were noted for CER 30 mg in the fed and fasted states.","Effect of food on the pharmacokinetics of once-daily cyclobenzaprine extended-release 30 mg: a randomized, open-label, crossover, single-centre study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19243207/),h,8,262091,DB00321,Amitriptyline
,19243207,t(max),"No appreciable differences in the shape of the mean plasma cyclobenzaprine concentration versus time profile, t(lag) (2 hours) or t(max) (fed: 8 hours; fasted: 6 hours) were noted for CER 30 mg in the fed and fasted states.","Effect of food on the pharmacokinetics of once-daily cyclobenzaprine extended-release 30 mg: a randomized, open-label, crossover, single-centre study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19243207/),h,6,262092,DB00321,Amitriptyline
,1281075,elimination half-life,Its elimination half-life (approximately 26 hours) makes it suitable for once daily administration.,"Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281075/),h,26,267086,DB00321,Amitriptyline
,3735103,total intrinsic clearance,"The total intrinsic clearance of dothiepin decreased from 165.5 to 121.1 L/h as the dose was increased from 50 to 150 mg, but there was no significant effect on the terminal half-life (approximately 20 h).",Pharmacokinetics of dothiepin in humans: a single dose dose-proportionality study. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735103/),[l] / [h],165,268346,DB00321,Amitriptyline
,3735103,total intrinsic clearance,"The total intrinsic clearance of dothiepin decreased from 165.5 to 121.1 L/h as the dose was increased from 50 to 150 mg, but there was no significant effect on the terminal half-life (approximately 20 h).",Pharmacokinetics of dothiepin in humans: a single dose dose-proportionality study. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735103/),[l] / [h],121,268347,DB00321,Amitriptyline
,3735103,terminal half-life,"The total intrinsic clearance of dothiepin decreased from 165.5 to 121.1 L/h as the dose was increased from 50 to 150 mg, but there was no significant effect on the terminal half-life (approximately 20 h).",Pharmacokinetics of dothiepin in humans: a single dose dose-proportionality study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735103/),h,20,268348,DB00321,Amitriptyline
,3735103,half-lives,"The corresponding half-lives of the three metabolites, which are dose independent, were approximately 24, 28, and 40 h, respectively.",Pharmacokinetics of dothiepin in humans: a single dose dose-proportionality study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735103/),h,24,268349,DB00321,Amitriptyline
,3735103,half-lives,"The corresponding half-lives of the three metabolites, which are dose independent, were approximately 24, 28, and 40 h, respectively.",Pharmacokinetics of dothiepin in humans: a single dose dose-proportionality study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735103/),h,28,268350,DB00321,Amitriptyline
,3735103,half-lives,"The corresponding half-lives of the three metabolites, which are dose independent, were approximately 24, 28, and 40 h, respectively.",Pharmacokinetics of dothiepin in humans: a single dose dose-proportionality study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735103/),h,40,268351,DB00321,Amitriptyline
,21432861,ch,The method had a chromatographic run time of 4 min and a linear calibration curve ranging from 0.05 to 10 ng/mL (r2 > 0.99).,Quantification of cyproheptadine in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry in a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21432861/),min,4,269886,DB00321,Amitriptyline
,21432861,run time,The method had a chromatographic run time of 4 min and a linear calibration curve ranging from 0.05 to 10 ng/mL (r2 > 0.99).,Quantification of cyproheptadine in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry in a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21432861/),min,4,269887,DB00321,Amitriptyline
,22074958,flow-rate,The mobile phase was a mixture of 65% water+1% formic acid and 35% of acetonitrile at a flow-rate of 0.5 mL/min.,Chlorpromazine quantification in human plasma by UPLC-electrospray ionization tandem mass spectrometry. Application to a comparative pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22074958/),[ml] / [min],0.5,269924,DB00321,Amitriptyline
,21704239,"C(max,ss)","Mean C(max,ss), C(min,ss), and C(avg,ss) were 41.1, 21.4, and 31.4 ng/mL, respectively.","Steady-state pharmacokinetics of once-daily cyclobenzaprine extended release: a randomized, double-blind, 2-period crossover study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704239/),[ng] / [ml],41.1,271570,DB00321,Amitriptyline
,21704239,"C(min,ss)","Mean C(max,ss), C(min,ss), and C(avg,ss) were 41.1, 21.4, and 31.4 ng/mL, respectively.","Steady-state pharmacokinetics of once-daily cyclobenzaprine extended release: a randomized, double-blind, 2-period crossover study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704239/),[ng] / [ml],21.4,271571,DB00321,Amitriptyline
,21704239,"C(avg,ss)","Mean C(max,ss), C(min,ss), and C(avg,ss) were 41.1, 21.4, and 31.4 ng/mL, respectively.","Steady-state pharmacokinetics of once-daily cyclobenzaprine extended release: a randomized, double-blind, 2-period crossover study in healthy volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704239/),[ng] / [ml],31.4,271572,DB00321,Amitriptyline
,21704239,"T(max,ss)","The median T(max,ss) for CER 30 mg was 7.0 hours, with a mean t(½) of 34.8 hours.","Steady-state pharmacokinetics of once-daily cyclobenzaprine extended release: a randomized, double-blind, 2-period crossover study in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704239/),h,7.0,271573,DB00321,Amitriptyline
,21704239,t(½),"The median T(max,ss) for CER 30 mg was 7.0 hours, with a mean t(½) of 34.8 hours.","Steady-state pharmacokinetics of once-daily cyclobenzaprine extended release: a randomized, double-blind, 2-period crossover study in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704239/),h,34.8,271574,DB00321,Amitriptyline
,21704239,R(ac),The R(ac) for CER was 2.65.,"Steady-state pharmacokinetics of once-daily cyclobenzaprine extended release: a randomized, double-blind, 2-period crossover study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704239/),,2.65,271575,DB00321,Amitriptyline
